Cristina Ortiz,
Ortiz “Moving forward”,
forward” 2014
2014,
mixed technique, 120 cm x 70 cm, from the exhibition “Aspirations”
Main Announcement
Madrid2017 Main Ann 1016.indd 1
4-11-2016 6:21:09
Table of Contents
ERA-EDTA Council............................................... Page 1
Invitation ................................................................ Page 3
Scientific Committee ............................................. Page 4
Important Addresses ............................................ Page 5
Congress Timetable ............................................... Page 6
Preliminary Scientific Programme ...................... Page 7
Submission of Abstracts ....................................... Page 23
Travel Grants.......................................................... Page 24
Abstract Categories ............................................... Page 25
Congress Information ........................................... Page 27
Congress Membership Rules and Deadlines .... Page 28
One World .............................................................. Page 29
About Madrid ........................................................ Page 30
Passport and Visa Information ............................ Page 32
Hotel Accommodation ......................................... Page 33
Hotel List ................................................................ Page 34
Important Deadlines ............................................. Page 35
Next ERA-EDTA Congresses ............................... Page 36
ERA-EDTA for You ............................................... Page 38
2
Madrid2017 Main Ann 1016.indd 2
4-11-2016 6:21:15
ERA-EDTA COUNCIL
President
Andrzej Wi cek, Poland
Secretary-Treasurer
Jonathan G. Fox, United Kingdom
Chairperson of the Administrative Offices
Markus Ketteler, Germany
Editor-in-Chief of “Nephrology Dialysis Transplantation”
Carmine Zoccali, Italy
Chairperson of the Registry
Ziad Massy, France
Ordinary Council Members
Angel Argiles Ciscart, France
Mustafa Arici, Turkey
Giovambattista Capasso, Italy
Pieter Evenepoel, Belgium
Danilo Fliser, Germany
(also Chairperson of the Paper Selection Committee)
Jolanta Malyszko, Poland
Alberto Ortiz, Spain
Goce Spasovski, F.Y.R. of Macedonia
Congress Presidents
Jorge B. Cannata-Andía, Spain
Andrzej Wi cek, Poland
www.era-edta.org
1
Madrid2017 Main Ann 1016.indd Sez1:1
4-11-2016 6:21:19
2
Madrid2017 Main Ann 1016.indd Sez1:2
4-11-2016 6:21:26
Invitation
Dear Colleagues and Friends,
We are strongly committed to have you come to Madrid in June of 2017 for the 54th ERA-EDTA
Congress.
This great event will occur 18 years after the last time we met in Madrid, which was also the last ERAEDTA Congress of the 20th century (1999). Since then, the ERA-EDTA Congresses have experienced
tremendous growth, with the number of participants tripling. Over this time, the ERA-EDTA itself
has also progressively expanded, leading European nephrology into the 21st century by developing
several major initiatives such as the modernisation of the Registry, continuing the development of the
two journals of the Association (NDT and CKJ), promoting active collaboration with many European
and other National and International medical societies, creating the ERA-EDTA Working Groups, etc.
We hope the attractive scientific programme we are preparing will meet your expectations: the
Scientific Committee, chaired by Peter Stenvinkel, has worked very hard to provide the latest cutting
edge science.
Among the pre-Congress activities, the ERA-EDTA will offer on the first day 22 CMEs and then the
main Congress will have 4 Plenary lectures, more than 60 Symposia, 33 mini-lectures, and several free
communications and poster sessions allocated in 10 different subject-driven tracks, in which the whole
spectrum of basic, clinical and translational nephrology, dialysis and transplantation will be covered
by more than 350 expert speakers from more than 30 different countries.
Apart from the outstanding scientific programme we hope you will enjoy, Madrid has a wide variety
of cultural and leisure opportunities. The city has great museums with the best of both classic and
contemporary arts, parks and friendly, charming and romantic corners. I am sure that Madrid will once
again be a friendly place to discuss science and to meet old and new friends alike.
We truly look forward to seeing you at the 54th ERA-EDTA 2017 Congress in Madrid!
Andrzej Wi cek
ERA-EDTA
ERA
ER
A ED
DTA P
Pre
President
resi
siide
dent
ntt
Jorge B. Cannata-Andía
Congress President,
on behalf of all the Nephrologists from Madrid
3
Madrid2017 Main Ann 1016.indd Sez1:3
4-11-2016 6:21:38
Scientific Committee
CONGRESS PRESIDENTS
Jorge B. Cannata-Andía, Spain
Andrzej Wi cek, Poland
SCIENTIFIC COMMITTEE
Chair: Peter Stenvinkel, Sweden
Kerstin Amann, Germany
Angel Argiles Ciscart, France
Edwina Brown, United Kingdom
Annette Bruchfeld, Sweden
Jorge B. Cannata-Andía, Spain
Olivier Devuyst, Switzerland
Ana Carina Ferreira, Portugal
Danilo Fliser, Germany
Jürgen Floege, Germany
Francesca Mallamaci, Italy
Jolanta Malyszko, Poland
Heini Murer, Switzerland
Gerjan Navis, The Netherlands
Alberto Ortiz, Spain
Ingrid Os, Norway
Goce Spasovski, F.Y.R. of Macedonia
Andrzej Wi cek, Poland
4
Madrid2017 Main Ann 1016.indd Sez1:4
4-11-2016 6:21:43
Important Addresses
SCIENTIFIC PROGRAMME
CONGRESS SECRETARIAT
ERA-EDTA President
Andrzej Wi cek
Department of Nephrology,
Transplantation and Internal Medicine
Medical University of Silesia in Katowice
Francuska 20-24
PL-40-027 Katowice
Poland
E-mail: [email protected]
ERA-EDTA Operative Headquarters
Via XXIV Maggio 38
I-43123 Parma
Italy
Phone: +39-0521-989078
Fax: +39-0521-959242
www.era-edta.org
Membership Office
Phone: +39-344-1409706
E-mail: [email protected]
Congress President
Jorge B. Cannata-Andía
Servicio de Metabolismo Óseo y Mineral
Instituto Reina Sofía de Investigación
C/Julián Clavería, s/n
33006 Oviedo
Spain
E-mail: [email protected]
Congress & Industry Relations
Paolo Zavalloni
ERA-EDTA Industry Relations
Via E. Mattei 92, int. 4
I-40138 Bologna
Italy
Phone: +39-345-4592758
Skype: PaoZav
E-mail: [email protected]
Chairperson of the Scientific Committee
Peter Stenvinkel
Department of Renal Medicine M99
Karolinska University Hospital
Huddinge
S-141 86 Stockholm
Sweden
E-mail: [email protected]
Registrations
E-mail: [email protected]
Phone: +39-345-0211784
+39-051-4595092
Official Housing Agent
AIM GROUP INTERNATIONAL MADRID OFFICE
C/Arturo Soria, 55 - Local 1
28027 Madrid
Spain
Phone: +34 91 2873400
Fax: +34 91 2873401
E-mail: [email protected]
5
Madrid2017 Main Ann 1016.indd Sez1:5
4-11-2016 6:21:45
Congress Timetable
Friday, June 2 2017 - REGISTRATION DAY
11.00 - 19.00
Registrations
Saturday, June 3 2017 - DAY 1
07.00 - 19.00
Registrations
08.30 - 16.15
CME Courses and Working Groups
17.00 - 18.30
Welcome Ceremony + Plenary Lecture 1
15.30 - 20.30
Exhibition open for visit
18.30 - 20.00
Welcome Reception
Sunday, June 4 2017 - DAY 2
07.30 - 18.45
08.00 - 09.30
Registrations
Symposia
Free Communications + Mini Lectures
09.30 - 10.45
Poster session, coffee break and exhibition visit
10.45 - 11.30
Plenary Lecture 2
11.45 - 13.15
Symposia
13.15 - 15.15
Free Communications + Mini Lectures
Industry Symposia
15.15 - 16.45
Symposia
Free Communications + Mini Lectures
17.00 - 18.30
Symposia
Free Communications + Mini Lectures
09.30 - 17.30
Exhibition open for visit
Monday, June 5 2017 - DAY 3
07.30 - 18.45
Registrations
08.00 - 09.30
Symposia
Free Communications + Mini Lectures
09.30 - 10.45
Poster session, coffee break and exhibition visit
ERA-EDTA General Assembly*
10.45 - 11.30
11.45 - 13.15
Plenary Lecture 3
Symposia
13.15 - 15.15
Free Communications + Mini Lectures
Industry Symposia
15.15 - 16.45
Symposia
Free Communications + Mini Lectures
17.00 - 18.30
Symposia
Free Communications + Mini Lectures
09.30 - 17.30
Exhibition open for visit
Tuesday, June 6 2017 - DAY 4
07.30 - 12.45
08.00 - 09.30
Registrations
Symposia
Free Communications + Mini Lectures
09.45 - 10.30
10.45 - 12.15
Plenary Lecture 4
Symposia
Free Communications + Mini Lectures
* open only to ERA-EDTA members
6
Madrid2017 Main Ann 1016.indd Sez1:6
4-11-2016 6:21:51
Preliminary Scientific Programme
PLENARY LECTURES
New vision of Uraemic Toxicity: not a matter of a
few compounds, we are facing a dreadful network
Alberto Ortiz, Madrid, Spain
New approaches towards kidney regeneration
Juan Carlos Izpisua Belmonte, La Jolla, CA, U.S.A.
Kidney disease in the elderly - is it only eGFR that
matters?
Edwina Brown, London, United Kingdom
Bioelectric medicine – how nerves modulate the
immune system
Kevin Tracey, Manhasset, NY, U.S.A.
Re-creating life
Steven Benner, Alachua, FL, U.S.A.
Heat stress nephropathy - implications in the
setting of global warming and water shortage
Richard J. Johnson, Denver, U.S.A.
Adipose tissue expandibility, lipotoxicity and
metabolic syndrome
Antonio Vidal-Puig, Cambridge, United Kingdom
Uric acid in metabolic syndrome: culprit or innocent
bystander?
Mehmet Kanbay, Istanbul, Turkey
MINI LECTURES
Phosphate binders in chronic kidney disease: a
systematic review of recent data
Jürgen Floege, Aachen, Germany
Update on sodium-dependent phosphate
transporters
Carsten Wagner, Zurich, Switzerland
Inflammation and innate immunity in CKDassociated vascular disease
Danilo Fliser, Homburg/Saar, Germany
Does kidney hypoxia precede albuminuria?
Fredrik Palm, Uppsala, Sweden
For 30 years we have been told that haemodiafiltration
is better - why haven’t we adopted it?
Angel Argiles Ciscart, Montpellier, France
Genome-wide association studies in nephrology
Anna Koettgen, Freiburg, Germany
Claudins in renal function
Markus Bleich, Kiel, Germany
“Primun non nocere” - Should statins and protein
pump inhibitors be used in CKD stage 5?
David Goldsmith, London, United Kingdom
SGLT2 - from rare disorders to new treatment for
diabetes
Luigi Gnudi, London, United Kingdom
Vitamin K deficiency - does it promote vascular
calcification?
Speaker to be confirmed
Classification and prognosis in IgA nephropathy
John Feehally, Leicester, United Kingdom
Altered circadian hemodynamic and renal function
in liver cirrhosis
Rajiv Agarwal, Indianapolis, U.S.A.
Rituximab versus cyclophosphamide for ANCAassociated vasculitis
Vladimir Tesar, Prague, Czech Republic
Balancing wobbles in the body sodium
Jens Titze, Nashville, U.S.A.
Subclinical pulmonary congestion is prevalent in
nephrotic syndrome
Francesca Mallamaci, Reggio Calabria, Italy
Navigating the critical transitional phase from
CKD5 to CKD5D
Kamyar Kalantar-Zadeh, Irvine, U.S.A.
Systems biology as a solution to better understand
kidney disease?
Joost Peter Schanstra, Toulouse, France
Molecular mediators of peritoneal fibrosis - role of
Vitamin D Receptor Activators (VDRAs)
Rafael Selgas, Madrid, Spain
7
Madrid2017 Main Ann 1016.indd Sez1:7
4-11-2016 6:21:51
Preliminary Scientific Programme
About renal and moral failure: the impact of the
refugee crisis in Europe
Wim Van Biesen, Ghent, Belgium
SYMPOSIA
Track 1
Fluid and electrolytes, tubular transport, physiology
How can we get immunized patients on our waiting
list transplanted?
Torbjörn Lundgren, Stockholm, Sweden
• Kinases in control of tubular transport
- The WNK-SPAK pathway in general
Dario Alessi, Dundee, United Kingdom
- WNK and the regulation of blood pressure
Juliette Hadchouel, Paris, France
- Kinases and potassium homeostasis
Johannes Loffing, Zurich, Switzerland
- Kinases and AQP2 trafficking
Giovanna Valenti, Bari, Italy
HCV: still a problem in dialysis and kidney TP
patients?
Michel Jadoul, Brussels, Belgium
Organ donation in the world - keys to success
Beatriz Dominguez-Gil, Madrid, Spain
Update on the role of mTOR inhibitors
Hallvard Holdaas, Oslo, Norway
• Cell biology in the renal tubule
- New developments on the inflammasome and IL-1
Hans-Joachim Anders, Munich, Germany
- Lipocalin 2 / NGAL: a player at the crossroad
of different signalling pathways leading to CKD
progression
Fabiola Terzi, Paris, France
- Endolysosomal disorders
Olivier Devuyst, Zurich, Switzerland
- Autophagy and senescence in proximal tubule
Roland Schmitt, Hannover, Germany
Clinical imaging of vascular disease in chronic
kidney disease
Marc Vervloet, Amsterdam, The Netherlands
What should nephrologists know about microRNAs
in chronic kidney disease?
Amaryllis Van Craenenbroeck, Antwerp, Belgium
Oral or intravenous iron? - that is the question
Iain C. Macdougall, London, United Kingdom
• Renal mineral handling - what’s new?
- Renal phosphate handling
Carsten Wagner, Zurich, Switzerland
- Magnesium
Markus Ketteler, Coburg, Germany
- FGF23-Klotho signalling in the kidney
Hannes Olauson, Stockholm, Sweden
- Modeling calcium transport
Aurélie Edwards, Paris, France
Serum sodium: association to all-cause and
cardiovascular mortality in chronic kidney disease
Philip A. Kalra, Salford, United Kingdom
Points of concern in post-AKI follow up
Norbert H. Lameire, Ghent, Belgium
Does early-start renal replacement therapy improve
outcomes for patients with acute kidney injury?
John Prowle, London, United Kingdom
Track 2
Hereditary disorders, development, pregnancy,
paediatric nephrology
• Actualities and new questions in adult polycystic
kidney disease
- Clinical scores in ADPKD: advantages and
limitations
Ron T. Gansevoort, Groningen, The Netherlands
- Signaling pathways in ADPKD: Novel targets for
treatment?
Speaker to be confirmed
8
Madrid2017 Main Ann 1016.indd Sez1:8
4-11-2016 6:21:51
Preliminary Scientific Programme
• Focal segment glomerulosclerosis - new insights
into pathomechanisms
- Lessons from the zebrafish
Jaakko Patrakka, Stockholm, Sweden
- Glomerular disease signalling in FSGS
Tobias Huber, Freiburg, Germany
- How does glomerular hypertrophy occur?
Marcus J. Moeller, Aachen, Germany
- Novel pathways in FSGS
Pierre-Louis Tharaux, Paris, France
- ADPKD - novel aspects on the role of vasopressin
Olivier Devuyst, Zurich, Switzerland
- ADPKD and mineral and bone disease - what are
the links?
Pieter Evenepoel, Leuven, Belgium
• Genetics of blood pressure regulation
- Population studies
Speaker to be confirmed
- Salt sensitivity: Insights from evolution
Matthew Bailey, Edinburgh, United Kingdom
- Resistant hypertension and pharmacogenomics
Speaker to be confirmed
- The WNK-SPAK pathway: Relevance for clinicians
Johannes Loffing, Zurich, Switzerland
• Glomerulonephritis: What is new in 2017?
- Membranous GN
Pierre Ronco, Paris, France
- IgAN
Jürgen Floege, Aachen, Germany
- Treatment of minimal change GN and FSGS
Piero Ruggenenti, Bergamo, Italy
- Heparanase - is it nephroprotective in nephrotic
syndrome?
Suheir Assady, Haifa, Israel
• Developmental origin of health and disease
- Birth weight and risk of CKD
Bjørn Egil Vikse, Haugesund, Norway
- Fetal programming of renal aging
Uyen Huynh-Do, Bern, Switzerland
- Targeting epigenetics of chronic kidney disease
Michael Zeisberg, Göttingen, Germany
- An update on inducible pluripotent stem cells
Joseph Bonventre, Boston, USA
• Hepatitis C, hepatitis B and HIV in the era of
effective antivirals
- Hepatitis C and direct antivirals - clinical
applications and indications
Annette Bruchfeld, Stockholm, Sweden
- Hepatitis C treatment: before or after renal
transplantation?
Michel Jadoul, Brussels, Belgium
- Hepatitis B - update on treatment and vaccination
Fabrizio Fabrizi, Milan, Italy
- Chronic kidney disease in the ageing HIVpositive population
Lene Ryom, Copenhagen, Denmark
• Immunology and hypertension during pregnancy
- Pregnancy in kidney transplanted women,
immunology and outcomes
Anna Varberg Reisaeter, Oslo, Norway
- Lupus and pregnancy
Uyen Huynh-Do, Bern, Switzerland
- Renal hemodynamic changes in health and disease
Speaker to be confirmed
- Preeclampsia - novel approaches for treatment
Speaker to be confirmed
• Complement abnormalities associated with C3
glomerulopathy
- C3 glomerulopathy: lessons from animal models
Matthew Pickering, London, United Kingdom
- Genetic abnormalities in C3GN
Santiago Rodriguez de Cordoba, Madrid, Spain
- Acquired abnormalities in C3GN
Speaker to be confirmed
- Recurrence of GC3 after renal transplantation,
risk factor, treatment and prevention
Moglie Le Quintrec, Montpellier, France
Track 3
Glomerular diseases, general clinical nephrology
• Non-invasive biomarkers of renal fibrosis or
progressive kidney diseases
- Humoral factors
Christos Chatziantoniou, Paris, France
- Non-invasive diagnostic of renal fibrosis
Peter Boor, Aachen, Germany
- Proteomics for chronic renal diseases
Gian Marco Ghiggeri, Genoa, Italy
- Metabolomics and-or Uremic Toxins
Raymond Vanholder, Ghent, Belgium
9
Madrid2017 Main Ann 1016.indd Sez1:9
4-11-2016 6:21:51
Preliminary Scientific Programme
• Fibrosis complicating several scenarios in
chronic kidney disease
- New mechanisms of cardiac fibrosis and failure
in chronic kidney disease
Javier Diez, Pamplona, Spain
- Role of ALK-1 and endoglin, members of the
TGF-beta receptor complex, in kidney fibrosis
José M. Lopez-Novoa, Salamanca, Spain
- Renal fibrosis - should we treat it? No!
Hans-Joachim Anders, Munich, Germany
- Renal fibrosis - should we treat it? Yes!
Rafael Kramann, Aachen, Germany
- Uric acid and renal outcomes - do we need
further evidence to lower uric acid in asymtomatic
patients?
José Luño, Madrid, Spain
- FGF23-Klotho axis and myocardial alterations in
CKD
Danilo Fliser, Homburg/Saar, Germany
- Cathepsins and endostatin in the cardiorenal
continuum
Johan Ärnlöv, Uppsala, Sweden
• Salt and the diseased kidney: an evil relationship
or a too blamed one?
- What are the links between sodium and the
immune system?
Speaker to be confirmed
- Effect of salt on the cutaneous antimicrobial
barrier function
Jens Titze, Nashville, U.S.A.
- Salt restriction in hemodialysis patient just a chimera?
Gerjan Navis, Groningen, The Netherlands
- How far can we go with low salt diet in elderly
CKD patients?
Mustafa Arici, Ankara, Turkey
Track 4
CKD - pathophysiology, epidemiology, prevention,
progression, ageing
• Chronic kidney disease - a clinical model of
premature ageing
- Reasons why CKD patients undergo premature
ageing
Peter Stenvinkel, Stockholm, Sweden
- Ageing and chronic inflammation - lessons from
non-renal chronic debilitating diseases
Jeroen Kooman, Maastricht, The Netherlands
- Recovering Klotho in CKD - is this an achievable
challenge?
Adriana Dusso, Oviedo, Spain
- Can ageing be drugged?
Paul Shiels, Glasgow, United Kingdom
• The uremic microbiota - Implications for the
uremic phenotype and treatment
- The gut microbiome and its relation to metabolic
alterations in CKD
Griet Glorieux, Ghent, Belgium
- The influence of renal transplantation on retained
microbial-human co-metabolites
Bjorn Meijers, Leuven, Belgium
- The leaky gut - relationship with the microbiota
Pieter Evenepoel, Leuven, Belgium
- Should we drug the bug - how can diet and drugs
influence the gut flora?
Denis Fouque, Lyon, France
• Kidney biomimcry - what can Nephrologists
learn from the animal kingdom?
- Lessons on how animals store water in relation
to global warming, obesity and CKD
Richard J. Johnson, Denver, U.S.A.
- Uric acid, fructose and metabolic syndrome.
An evolutionary approach to today’s epidemic
Miguel Lanaspa, Denver, U.S.A.
- What can we learn from the animal kingdom
about renal sodium and water handling?
Nadine Bouby, Paris, France
- What can hibernating bears teach us on how to
prevent muscle and bone loss in CKD?
Peter Stenvinkel, Stockholm, Sweden
• Physical exercise and lifestyle management in
chronic kidney disease
- Physical exercise in CKD. Evidence from clinical
trials
Carmine Zoccali, Reggio Calabria, Italy
- The Excite trial: results of a home based exercise
in dialysis patients
Francesca Mallamaci, Reggio Calabria, Italy
- Modifiable lifestyle factors in high risk individuals
with CKD
Rainer Oberbauer, Vienna, Austria
• Biomarkers in chronic kidney disease
- Prognostic and predictive biomarkers in CKD
Gert Mayer, Innsbruck, Austria
10
Madrid2017 Main Ann 1016.indd Sez1:10
4-11-2016 6:21:52
Preliminary Scientific Programme
• Iron - the bright and the dark side
- Iron in dialysis - is it a panacea or toxin?
Jolanta Malyszko, Bialystok, Poland
- Iron and infections - do we put fuel on the fire?
Günter Weiss, Innsbruck, Austria
- Iron overload - should Nephrologists care?
Iain C. Macdougall, London, United Kingdom
- Fe-based phosphate binders - a role in iron
supplementation or a dead end?
Markus Ketteler, Coburg, Germany
- Self-management and e-health initiatives
Andrea W. Evers, Leiden, The Netherlands
• New insigths into progressive chronic kidney
disease
- Progressive CKD - who is at risk?
Manuel Praga, Madrid, Spain
- Effects of stress-induced dedifferentiation of
renal epithelia in chronic kidney disease
Hermann-Josef Groene, Heidelberg, Germany
- Clinical utility of biomarkers for CKD
progression
Gunnar Heine, Homburg/Saar, Germany
- Current treatment options for “fast” CKD
progressors
Piero Ruggenenti, Bergamo, Italy
• Residual renal function in HD - an opportunity
for improvement
- Longer or more frequent dialysis: is residual
renal function best at stake?
Charles Chazot, Sainte Foy Les Lyon, France
- “To pee or not to pee” - is there a place for
diuretics in dialysis patients?
Angel Argiles Ciscart, Montpellier, France
- Should we stop ACE/ARBs in CKD stage 5?
Muhammad Magdi Yaqoob, London, United
Kingdom
- Assessment of fluid overload in dialysis patients
Adrian Covic, Iasi, Romania
• Epidemiology and CKD-MBD
- The challenge of improving observational
studies in CKD. The causal inference or Causal
inference in CKD research
Speaker to be confirmed
- CKD-MBD targets: Contribution of COSMOS
Jorge B. Cannata-Andía, Oviedo, Spain
- COSMOS: PTH lowering drugs and
parathyroidectomy - Impact on outcomes
Speaker to be confirmed
- Clinical use of ALP and PTH in discrimination of
low vs high bone turnover
Goce Spasovski, Skopje, F.Y.R. of Macedonia
• Heart failure in chronic kidney disease
- Mineralocorticoid receptors and heart failure
Ziad Massy, Paris, France
- Treatment of hyperkalemia in dialysis patients:
what is on the horizon?
Matthew R. Weir, Baltimore, U.S.A.
- Rhythm disturbances - the silent killer
Christiane Drechsler, Würzburg, Germany
- What is the utility of cardiovascular biomarkers?
Jesus Egido, Madrid, Spain
Track 5
End Stage Renal Disease, haemodialysis
• Are we offering good care to the elderly with
kidney disease?
- The characteristics of incident dialysis patients from
the sixties to the present: age and co-morbidities
Kitty J. Jager, Amsterdam, The Netherlands
- Elderly patients reaching end-stage renal disease:
treat or not to treat?
Maurice Laville, Lyon, France
- If we treat elderly patients with dialysis - is there
a point to stop?
Edwina Brown, London, United Kingdom
- Is advanced care planning the solution and do
we apply it?
José Antonio Sanchez-Tomero, Madrid, Spain
• Bone loss in chronic kidney disease
- Interrelations of Wnt inhibitors, vascular
calcification and bone loss
Jorge B. Cannata-Andía, Oviedo, Spain
- Vitamin D - a drug for all seasons?
David Goldsmith, London, United Kingdom
- Sclerostin in CKD - is it a mediator of vascular
and bone disease or just another biomarker?
Vincent Brandenburg, Aachen, Germany
- Novel treatment of adynamic bone disease
Mario Cozzolino, Milan, Italy
11
Madrid2017 Main Ann 1016.indd Sez1:11
4-11-2016 6:21:52
Preliminary Scientific Programme
• Hemodialysis anticoagulation: present and future
- Anticoagulation for extracorporeal therapies
Andrew Davenport, London, United Kingdom
- Is regional citrate anticoagulation the future of
hemodialysis?
Jadranka Buturovic-Ponikvar, Ljubljana, Slovenia
- Citrate anticoagulation for CRRT - current status
and challenges
Helena Maria Oudemans-Van Straaten,
Amsterdam, The Netherlands
- Citrate in dialysate: standard for the next decade
hemodialysis?
Speaker to be confirmed
Track 6
Home therapies, peritoneal dialysis
• Use of home-based therapies in Europe a missing link?
- PD use is declining in Europe - why?
Marlies Noordzij, Amsterdam, The Netherlands
- Should we start PD acutely?
Speaker to be confirmed
- We should enable patients to decide
Olof Heimbürger, Stockholm, Sweden
- Why stimulating home based therapies is an
economical imperative that has ethical consequences
Bert Bammens, Leuven, Belgium
• Muscle mass and fat mass in chronic kidney
disease - assessment and implications
- Assessment of Protein-Energy Wasting - quest
for the gold standard
Pieter M. Ter Wee, Amsterdam, The Netherlands
- The dual impact of under- and overweight
on morbidity and mortality in chronic kidney
disease
Juan Jesus Carrero, Stockholm, Sweden
- Can chronic kidney disease patients improve
their muscle mass by nutritional means?
Denis Fouque, Lyon, France
- Physical activity intervention - is it realistic in
sedentary dialysis patients?
Amaryllis Van Craenenbroeck, Antwerp, Belgium
• Peritoneal dialysis and cardiovascular risk
- Achieving euvolaemia in PD patients - lessons
from a clinical case
Jeroen Kooman, Maastricht, The Netherlands
- Biomarkers for vascular calcification in
peritoneal dialysis
Ricardo Correa-Rotter, Mexico City, Mexico
- Blood pressure targets in PD - what is the
evidence?
James Heaf, Copenhagen, Denmark
- Gut microbiota in PD
Griet Glorieux, Ghent, Belgium
• Dialysis for the ageing population
- Dialysis in the elderly - a different ball game?
Wim Van Biesen, Ghent, Belgium
- Geriatric assessment as standard nephrological care
Edwina Brown, London, United Kingdom
- What outcomes should Nephrologists measure
in the ageing dialysis population?
Ingrid Os, Oslo, Norway
- Dialysis withdrawal - when, how and why
Monika Lichodziejewska-Niemierko, Gdańsk,
Poland
• The ugly new faces of old enemies - bacterial
infections in nephrology
- Bacteriemia and sepsis - relation to hemodialysis
catheters
James Tattersall, Leeds, United Kingdom
- New aspects on PD-related peritonitis
Norbert H. Lameire, Ghent, Belgium
- Update on urinary tract infection and urosepsis
for the Nephrologist
Jonathan G. Fox, Glasgow, United Kingdom
- “What´s the cause of those so ill? - that damned
elusive difficile”. The emerging treat of
Clostridium difficile infections
Marcin Adamczak, Katowice, Poland
12
Madrid2017 Main Ann 1016.indd Sez1:12
4-11-2016 6:21:52
Preliminary Scientific Programme
- Mesenchymal stem cell transfusion for
desensitization of positive lymphocyte crossmatch before kidney transplantation
Gamal Saadi, Cairo, Egypt
- Monitoring of immunosuppressive drugs
metabolites in kidney transplantation - helpful
or dispensable?
Leszek Paczek, Warsaw, Poland
- The fine line between under- and
overimmunosuppression - impact of natural
products and dietary supplements
Steven Gabardi, Boston, U.S.A.
Track 7
Transplantation, immunology
• Management of complications after kidney
transplantation (I)
- Is severe obesitys of any harm in living kidney
donation?
Andrzej J. Wi cek, Katowice, Poland
- Pretransplant weight loss in dialysis patients how important is it?
Mehmet Sukru Sever, Istanbul, Turkey
- Evolution and management of bone disease after
transplantation
Pieter Evenepoel, Leuven, Belgium
- Evolution and management of arterial stiffness
after renal transplantation
George Reusz, Budapest, Hungary
• Advances in drug treatment after renal
transplantation
- Steroid-free or not?
Paolo Malvezzi, Grenoble, France
- Update on Belatacept and IdeS in renal
transplantation
Bengt Fellström, Uppsala, Sweden
- Any new immunosuppressives on the horizon?
Josep M. Grinyó, Barcelona, Spain
- Update on antiviral treatment in kidney
transplant recipients
Fabrizio Fabrizi, Milan, Italy
• Management of complications after kidney
transplantation (II)
- Malignancy after kidney transplantation what should nephrologists know?
Alicja Debska-Slizien, Gdansk, Poland
- The natural history of kidney graft cortical
microcirculation
Rafael Selgas, Madrid, Spain
- Why should we assess the biological age of the
renal transplant?
Paul Shiels, Glasgow, United Kingdom
- Management of chronic graft rejection
Daniel Abramowicz, Antwerp, Belgium
Track 8
Hypertension, diabetes, vascular disease
• Novel aspects of management of blood pressure
in chronic kidney disease
- How to obtain the target blood pressure in CKD:
is it a SPRINT or a marathon?
Rajiv Agarwal, Indianapolis, U.S.A.
- Renal denervation and CKD progression
Peter J. Blankestijn, Utrecht, The Netherlands
- Mineralocorticoid receptor blockers in CKD
patients
Matthew R. Weir, Baltimore, U.S.A.
- Optimal treatment for drug-resistant
hypertension
Speaker to be confirmed
• Therapeutic use of renal progenitor and adult
renal cells for kidney regeneration
- Therapeutic use of renal progenitor cells for
chronic kidney disease
Benedetta Bussolati, Turin, Italy
- Therapeutic use of renal progenitor cells for
acute kidney disease
Joseph Bonventre, Boston, USA
- Organoid models and applications in biomedical
research
Giuseppe Remuzzi, Bergamo, Italy
- Cell therapy with adult renal-derived cells clinical experience
Torbjörn Lundgren, Stockholm, Sweden
• Cardiovascular disease in patients with chronic
kidney disease - double trouble
- Role of Klotho and FGF23 in uremic cardiomyopathy
Marc Vervloet, Amsterdam, The Netherlands
- Hormones and uremic cardiomyopathy
Andrzej J. Wi cek, Katowice, Poland
• Immunosuppression after renal transplantation less, more or appropriate?
- Innovative monitoring tools of immunosuppression
after kidney transplantation
Rainer Oberbauer, Vienna, Austria
13
Madrid2017 Main Ann 1016.indd Sez1:13
4-11-2016 6:21:52
Preliminary Scientific Programme
- Heart failure in kidney patients - a difficult
diagnosis with poor prognosis
Speaker to be confirmed
- What´s new in the diagnosis and treatment of
coronary artery disease in CKD?
Philip A. Kalra, Salford, United Kingdom
- New experimental evidence in pathogenesis of
diabetic nephropathy
Bo Feldt-Rasmussen, Copenhagen, Denmark
- Optimal treatment of diabetic patient with
albuminuria
Peter Rossing, Gentofte, Denmark
- Clinical care of diabetic kidney disease:
advantages of the early referral
Alberto Martinez-Castelao, Barcelona, Spain
• SGLT-2 inhibitors in diabetic kidney disease
- SGLT-2: role in physiology and pathophysiology
Dominique Prié, Paris, France
- SGLT-2: renal pathophysiology
Luigi Gnudi, London, United Kingdom
- SGLT-2 inhibition: clinical data
Christoph Wanner, Würzburg, Germany
- SGLT-2 inhibition: effects on blood pressure
Speaker to be confirmed
Track 9
Acute Kidney Injury, intensive care nephrology
• Detection and prevention of AKI in patients at
risk - state-of-the art 2017
- Are new AKI biomarkers of any clinical
advantage?
Raymond Vanholder, Ghent, Belgium
- Tubular dysfunction as a pathway for acute
kidney injury
Fredrik Palm, Uppsala, Sweden
- Ischaemic preconditioning: promise unfulfilled
Muhammad Magdi Yaqoob, London, United
Kingdom
- Are there novel pharmacological tools for AKI
prevention in 2017?
Norbert H. Lameire, Ghent, Belgium
• Novel drugs in chronic kidney disease
- Update on endothelin and mineralocorticoid
receptor antagonists
Johannes F.E. Mann, Munich, Germany
- Update on anticoagulants in CKD
Karolina Szummer, Stockholm, Sweden
- CCR2 inhibition: a panacea for diabetic kidney
disease
Matthew R. Weir, Baltimore, U.S.A.
- HIF prolyl hydroxylase inhibitors for the
treatment of renal anaemia and beyond
Kai-Uwe Eckardt, Erlangen, Germany
• Management of AKI patients in the ICU
- Blood pressure management in ICU patients
with AKI
Speaker to be confirmed
- Diuretics in AKI - yes, no or maybe?
Speaker to be confirmed
- RRT in AKI: when, how and how much?
Claudio Ronco, Vicenza, Italy
- Anticoagulation strategies for AKI patients
requiring RRT
Achim Joerres, Cologne, Germany
• Diabetic nephropathy - how should it be treated?
- HbA1c - is it optimal for glycemic control
assessment in chronic kidney disease?
Loreto Gesualdo, Bari, Italy
- Is there still a place for dual RAS blockade in
nephroprotection of diabetic patients?
Giuseppe Remuzzi, Bergamo, Italy
- Treatment of hyperglycemia in chronic kidney
disease
Bo Feldt-Rasmussen, Copenhagen, Denmark
- Haemodialysis-induced hypoglycaemia and
glycaemic disarrays in the uremic milieu
Ivan Rychlik, Prague, Czech Republic
• Special condition in the ICU requiring
nephrological advice
- Patients with life-threatening systemic disease at
the ICU
Vladimir Tesar, Prague, Czech Republic
- Management of cardiorenal syndromes in the ICU
Claudio Ronco, Vicenza, Italy
• Diabetic nephropathy - new trends in 2017
- Diabetic nephropathy in Europe: Epidemiology
and choice of renal replacement therapy
Marlies Noordzij, Amsterdam, The Netherlands
14
Madrid2017 Main Ann 1016.indd Sez1:14
4-11-2016 6:21:52
Preliminary Scientific Programme
- How much antibiotics does your RRT consume
per day? Pharmacokinetics of critically ill
patients undergoing RRT
Jan T. Kielstein, Braunschweig, Germany
- An overview of treatment of crush syndrome
Mehmet Sukru Sever, Istanbul, Turkey
- EURODOPPS: Selected findings from the calls
for proposals
Speaker to be confirmed
• Ethics in scientific research
- Ethics of intervention in small or large scale
disasters
- Do ethics and health economics always go hand
to hand?
- The interaction between public policy/financial
constraints and ethical values in treating patients
with renal failure
- What is more ethical for deceased graft donation:
opting in or opting out?
SPECIAL & JOINT SYMPOSIA
• NDT Polar Views. Risk prediction tools in
stage 5 D CKD: precious instruments for risk
stratification or just gadgets of electronic
wizardry?
- CON. Most clinical risk scores are useless
Friedo W. Dekker, Leiden, The Netherlands
- PRO. It’s time to implement risk scores in CKD
care
Navdeep Tangri, Winnipeg, Canada
• YNP – Young Nephrologists’ Platform
• Late Breaking Clinical Trials
• The Lancet
• ERA-EDTA Registry
- Ten year trends of renal transplantation in
recipients aged 75 years and older
Maria Pippias, Amsterdam, The Netherlands
- Characteristics and outcomes of patients with
systemic sclerosis (scleroderma) requiring RRT
Speaker to be confirmed
- Modification of the “long gap” phenomenon by
hemodialysis treatment time
Speaker to be confirmed
- Gender differences in advanced CKD
Speaker to be confirmed
- Recovery of renal function in paediatric RRT
Marjolein Bonthuis, Amsterdam, The Netherlands
• ERA-EDTA & European Society
of Cardiology (ESC)
• Optimizing care in advanced CKD and the
transition to dialysis: Insights
from DOPPS Program
- The DOPPS Program: invitation to collaborators
Hugh Rayner, Birmingham, United Kingdom
- CKDopps: Improving outcomes in advanced
CKD and the transition to dialysis
Helmut Reichel, Villingen-Schwenningen,
Germany
- DOPPS: Impact of clinical practices on early
mortality among HD patients
Speaker to be confirmed
- PDOPPS: Predictors of early successful PD use
Martin Wilkie, Sheffield, United Kingdom
• ERA-EDTA & European Association of the Study
of Diabetes (EASD)
• ERA-EDTA & European Society
of Hypertension (ESH)
• ERA-EDTA & European Society
for Paediatric Nephrology (ESPN)
• ERA-EDTA & Japanese Society
of Nephrology (JSN)
• American Society of Nephrology
Highlights (ASN)
15
Madrid2017 Main Ann 1016.indd Sez1:15
4-11-2016 6:21:53
Preliminary Scientific Programme
Part II - Individualized (personalized) treatment
of glomerular disease – is it already possible?
- Personalized immunomonitoring and treatment
in lupus nephritis
Hans-Joachim Anders, Munich, Germany
- Personalized monitoring and treatment in
membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
- Personalized approach to IgA nephropathy, is
supportive care the response for most patients?
Renato Monteiro, Paris, France
- Personalized treatment in ANCA-associated
vasculitis
Mårten Segelmark, Linköping, Sweden
- Hematuria in glomerular disease - is it important
for the outcome of the patients?
Jesus Egido, Madrid, Spain
CME COURSES
• Cross-talk in Renal Epidemiology
- Sample size calculations
Marlies Noordzij, Amsterdam, The Netherlands
- The contribution of cross sectional studies to
nephrology
Giovanni Luigi Tripepi, Reggio Calabria, Italy
- Using a joint model to describe progression and
mortality in patients with CKD
Vianda Stel, Amsterdam, The Netherlands
- Restricted mean survival time: an alternative to
the hazard ratio
Cecile Couchoud, Saint Denis La Plaine, France
- The importance of considering competing
treatment affecting prognosis in RCTs
Speaker to be confirmed
- Marginal structural models in clinical research:
when and how to use them
Pietro Ravani, Calgary, Canada
- Can we use routine primary care data to estimate
how many people with CKD there are? An
example using UK primary care data
Dorothea Nitsch, London, United Kingdom
• Novel therapeutic opportunuties to decrease
cardiovascular risk in CKD
EURECA-m Working Group (EUropean
an
REnal and CArdiovascular Medicine)
Part I - Novel risk factors and structurall
cardiovascular damage
- Chronic infections and cardiovascular risk: a
poorly understood link
Charles Ferro, Birmingham, United Kingdom
- Atrial fibrillation in CKD
Gunnar Heine, Homburg/Saar, Germany
- Novel faces of FGF23; iron deficiency, inflammation,
insulin resistance, proteinuria and acute kidney
injury
Mehmet Kanbay, Istanbul, Turkey
- Vascular calcifications in end stage kidney disease
Marianne Verhaar, Utrecht, The Netherlands
Part II - Ions and blood pressure
- Cardiovascular risk in CKD: novel insights from
the NEFRONA and ILERVAS studies
Jose M Valdivielso, Lérida, Spain
- Early Vascular Aging (EVA syndrome) in
CKD/ESRD
Gérard London, Fleury-Mérogis, France
- Blood pressure variability in patients with
chronic kidney disease
Pantelis Sarafidis, Thessaloniki, Greece
- ABPM in renal transplant patients: for everybody
and why?
Francesca Mallamaci, Reggio Calabria, Italy
• News in the pathogenesis and treatment of
glomerular disease
IWG (Immunonephrology Working Group)
Part I - Complement mediated diseases:
pathogenesis, new entities, upcoming
treatments, how to handle expensive drugs
- Complement activation in immune-mediated
glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
- Complement staining in kidney biopsy (C3, C4,
C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
- Complement in ANCA-associated Vasculitis new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
- Complement activation in IgA nephropathy,
membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
- Targeting complement in atypical hemolytic
uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy
16
Madrid2017 Main Ann 1016.indd Sez1:16
4-11-2016 6:21:56
Preliminary Scientific Programme
Debate:
- Haemodiafiltration has no advantage over high
flux haemodialysis
Steven Van Laecke, Ghent, Belgium
- High volume haemodiafiltration, the new
standard of treatment
Peter J. Blankestijn, Utrecht, The Netherlands
• Hot topics in the management of pre- and postkidney transplantation
DESCARTES Working Group (Developing
Education Science and Care for Renal
Transplantation in European States) In collaboration with EKITA, the
Organ Expert Section of ESOT on kidney
transplantation in Europe
- Survival with transplantation and dialysis implications for access to the waiting list?
Gabriel C. Oniscu, Edinburgh, United Kingdom
- You and your patient decide: take an old kidney
or remain on dialysis
Julio Pascual, Barcelona, Spain
- Pre-Transplant cardiac work-up before waitlisting – What’s in it for the individual patient
Patrick Mark, Glasgow, United Kingdom
- When and how to adjust immunosuppressive
therapy in patients with post-transplant
malignancy
Speaker to be confirmed
- Treatment of recurrent IgA nephropathy after
kidney transplantation
Giuseppe Grandaliano, Foggia, Italy
- Managing drug interactions with new drugs in
transplant recipients: practical recommendations
for nephrologists
Umberto Maggiore, Parma, Italy
- How to desensitize HLA incompatible kidney
transplant recipients
Lionel Rostaing, Grenoble, France
• DIABESITY: Diabetes and Obesity in Renal Disease
DIABESITY (Working Group researching on the
nephrological impact in relation
to diabetes and obesity)
- Hemodialysis or peritoneal dialysis treatment for
obese diabetic patients?
Robert Ekart, Maribor, Slovenia
- SGLT2 inhibitors for diabetic renal disease and
obesity: a new weapon in our pharmacological
armamentarium?
Christoph Wanner, Würzburg, Germany
- Reducing weight to slow GFR decline in patients
with obesity and diabetes: The CRESO study
Piero Ruggenenti, Bergamo, Italy
- Precision medicine in diabetic nephropaty in
obesity-time rethink treatment?
Peter Rossing, Gentofte, Denmark
- How can obesity-related nephropathy be identified
in clinical practice?
Manuel Praga, Madrid, Spain
- Renal histology in patients with type 2 diabetes
without proteinuria
Esteban Porrini, Tenerife, Spain
• Phosphate and Nutrition in CKD
ERN Working Group (European Renal
Nutrition)
- Intestinal phosphate absorption from nutrients
Pablo Antonio Ureña Torres, Saint Ouen, France
- Lowering phosphate intake without PEW:
is it possible during CKD, dialysis and
transplantation?
Pieter M. Ter Wee, Amsterdam, The Netherlands
- Phosphorus additive in food: a health risk for
CKD patients
Adamasco Cupisti, Pisa, Italy
- How can we modify nutrient habits toward a
lower phosphate intake?
a) Age and psychosocial factors
Speaker to be confirmed
b) Education and information: make a choice,
nutritional education program
Stanislas Trolonge, Bordeaux, France
• Impoving the outcome of dialysis
EUDIAL Working Group
(European Dialysis)
- Starting haemodialysis - an incremental
approach
Carlo Basile, Acquaviva delle Fonti, Italy
- Dialysis adequacy does everyone need the
same Kt/V
Andrew Davenport, London, United Kingdom
- Assessing volume in haemodialysis patients are
lung ultrasound and bioimpedance needed
Sandip Mitra, Manchester, United Kingdom
- Preventing intra-dialytic hypotension or does
haemdiafiltration improve growth in children
with end stage kidney disease
Rukshana Shroff, London, United Kingdom
17
Madrid2017 Main Ann 1016.indd Sez1:17
4-11-2016 6:21:57
Preliminary Scientific Programme
- Mediterranean diet: an optimal diet for CKD
patients?
Miguel A. Martinez-Gonzalez, Pamplona, Spain
- Position in CKD of novel compounds to treat
bone disease
Sandro Mazzaferro, Rome, Italy
- Any position left for active vitamin D?
Mario Cozzolino, Milan, Italy
Invited lecture:
- Update on CKD-MBD in Pediatrics
Rukshana Shroff, London, United Kingdom
• Diagnosis and management of inherited kidney
diseases: What’s New?
d
WGIKD (Working Group on Inherited
Kidney Disorders)
Part I
- Collagen IV glomerulopathies: An underdiagnosed
phenotypic chameleon?
Constantinos Deltas, Nicosia, Cyprus
- Alport Syndrome: A treatable hereditary kidney
disease
Oliver Gross, Göttingen, Germany
- NGS podocytopathy panel screening in adults
with CKD of unknown origin: Findings from the
GCKD Study
Anna Koettgen, Freiburg, Germany
Part II
- C3 glomerulopathy: Role of complement for
pathogenesis and treatment
Marina Vivarelli, Rome, Italy
- Advances in molecular understanding of cystinosis:
Implications for therapy
Speaker to be confirmed
- Preimplantation genetic diagnosis for inherited
renal diseases
Nine Knoers, Utrecht, Netherlands
- The European Reference Network for Rare Kidney
Diseases
Franz Schaefer, Hidelberg, Germany
• The new uraemic toxins and innovative
endeavors to treat uraemic toxicity
EUTox Working Group (European
Uremic Toxin)
- An update on uremic toxins: concepts and
novelties
Flore Duranton, Montpellier, France
- Lanthionine, a prospective novel uremic toxin, in
the context of sulfur metabolism derangement in
uremia
Alessandra Perna, Naples, Italy
- Aryl hydrocarbon receptor (AHR) and the
uremic toxins
Stéphane Burtey, Marseille, France
- Can we dominate and master renal cells to
remove uraemic toxins on request?
Rosalinde Masereeuw, Utrecht, Netherlands
- Using convection at its best to increase uraemic
toxin removal
Angel Argiles Ciscart, Montpellier, France
- Dissociating protein bound toxins to remove them
Joachim Jankowski, Aachen, Germany
- Adsorptive strategies to remove uraemic toxins
Tobias Beck, Aachen, Germany
• Implementation of the KDIGO update on CKDMBD
CKD-MBD (Working Group on Chronic Kidney Disease
- Mineral and Bone Disorders)
Part I
- Should the presence of vascular calcification
influence choice of phosphate binder?
Speaker to be confirmed
- Phosphate binder therapy in predialysis? When
and how?
Adrian Covic, Iasi, Romania
- Current insights into dietary intervention to
modulate phosphate concentration and balance
Vincent Brandenburg, Aachen, Germany
Part II
- Screening for fracture risk in CKD
Pablo Antonio Ureña Torres, Saint-Ouen, France
• Good guidance can save your patientt
European Renal Best Practice
- Selected topics from the ERBP Vascular Access
Guideline
Markus Hollenbeck, Bottrop, Germany
- Risk prediction models for elderly people with
Chronic Kidney Disease: a risky business?
Maarten Taal, Derby, United Kingdom
- Reading a systematic review: a hands-on
experience
Christiane Drechsler, Würzburg, Germany
- Why good guidance can save lives - or make
them better
Evi Nagler, Ghent, Belgium
18
Madrid2017 Main Ann 1016.indd Sez1:18
4-11-2016 6:22:00
Preliminary Scientific Programme
• Rheumatology for nephrologists
- My CKD patient has joint or back pain:
a diagnostic primer for nephrologists
Julio Pascual, Barcelona, Spain
- Sarcoidosis - How often do we miss renal
involvement?
Speaker to be confirmed
- Bacterial microbiota in ANCA Vasculitis: clinical
implications on the good, bad, and ugly
Andreas Kronbichler, Innsbruck, Austria
- Autoinflammatory diseases – an update for
nephrologists
Birgit Kortus-Götze, Marburg, Germany
- Antiphospholipid antibody syndrome:
a catastrophic disease?
Ricard Cervera, Barcelona, Spain
- Lupus: the ten top tips nephrologists must know
Frederic Houssiau, Brussels, Belgium
- Epidemiología de la ERC en Iberoamérica:
a) La realidad de Latinoamérica. ¿De qué
depende la heterogeneidad?
Walter Guillermo Douthat, Córdoba, Argentina
b) La realidad de España y Portugal: Desafíos a
corto plazo
Speaker to be confirmed
Mesa II: Problemas en Nefrología:
Envejecimiento, salud renal y reflexiones sobre
el futuro de la especialidad
- Salud renal y economía: ¿Podemos aspirar a la
sostenibilidad?
Angel Luis Martin de Francisco, Santander, España
- Envejecimiento, senescencia celular y ERC.
¿Podríamos actuar?
Diego Rodriguez Puyol, Alcalá de Henares, España
- Futuro de la Especialidad: ¿Qué dejar de hacer y
en qué innovar?
Mariano Rodríguez-Portillo, Córdoba, España
Mesa III: Guías de Práctica Clínica y Cuestiones
Emergentes en Nefrología
- CKD-MBD: ¿Correlacionan los marcadores
bioquímicos con la histología ósea? La
experiencia mundial K/DIGO
Ezequiel Bellorin-Font, Caracas, Venezuela
- Enfermedad de Fabry: Estudio PREFINE, un
desafío necesario
José-Vicente Torregrosa, Barcelona, España
- ¿Qué aportan las nuevas guías españolas de
accesos vasculares?
José Ibeas, Barcelona, España
- ¿Es frecuente la hipertensión pulmonar en
hemodiálisis? Factores implicados
Juan M. López-Gómez, Madrid, España
• Oncology for nephrologists
Part I
- Cytotoxic drugs and their effects on the kidney
Ben Sprangers, Leuven, Belgium
- Kidney and cancer - a dangereux liason
Alicja Debska-Slizien, Gdansk, Poland
- Targeted therapies in oncology and nephrotoxicity
Petra Tesarova, Prague, Czech Republic
- Challenging but helpful Nephrology consults in
the oncology ward
Jolanta Malyszko, Bialystok, Poland
Part II
- Dialysis and malignancy - a growing problem
Maria Pippias, Amsterdam, The Netherlands
- Patient with prior malignancy on the waiting list
for transplantation
Bruno Watschinger, Vienna, Austria
- From “primary” amyloidosis to monoclonal
gammopathy of renal significance - holistic
approach to plasma cell dyscrasias
Elena Zakharova, Moscow, Russia
- Oncology drugs in patients with CKD - a real
challenge
Jan T. Kielstein, Braunschweig, Germany
• Practical issues in vascular access care
- Vascular access stenosis: Steps in the diagnosis
and management
Ramon Roca-Tey, Barcelona, Spain
- Ultrasonography of the vascular access from
theory to clinical practice
Simon Van Hooland, Ghent, Belgium
- How to correct and avoid vascular access
malposition
Maria Guedes Marques, Coimbra, Portugal
- How to prevent and treat vascular access
complications
José Ibeas, Barcelona, Spain
- Central vein catheters in haemodialysis. How to
improve its performance
Maurizio Gallieni, Milan, Italy
• Curso de Nefrologia
(Nephrology Course in Spanish)
Mesa I: Introducción al Curso y Epidemiología
de la Enfermedad Renal Crónica (ERC) en
Iberoamérica
- Introducción al Curso
Maria Dolores Del Pino Y Pino, Almería, España
19
Madrid2017 Main Ann 1016.indd Sez1:19
4-11-2016 6:22:01
Preliminary Scientific Programme
• What adult nephrologists should know about
childhood-onset kidney disorders
- Diagnosis, management and outcomes of
congenital and inherited kidney diseases along
the age continuum
Elke Wuehl, Heidelberg, Germany
- Early management and long-term outcomes of
childhood idiopathic nephrotic syndrome
Nicholas Webb, Manchester, United Kingdom
- Structured transition of pediatric patients to
adult care: challenges and opportunities
Lars Pape, Hannover, Germany
- Resist the beginnings: Preserving cardiovascular
health in childhood-onset chronic kidney disease
Rukshana Shroff, London, United Kingdom
- Recruiting high calibre fellows into Nephrology:
Challenges and Solutions
Nadine Vogelsang, Münster, Germany
- Progressing training harmonisation.
The “European Certificate in Nephrology”
David Lappin, Galway, Ireland
- Knowledge-based examination in Nephrology:
The UK experience
Jonathan G. Fox, Glasgow, United Kingdom
- Mapping future progress. Panel and audience
general discussion lead by Anibal Ferreira,
Lisbon, Portugal and Itzchak Slotki, Jerusalem,
Israel
• Emerging global causes of chronic kidney disease
- Heat stress nephropathy
Richard J. Johnson, Denver, U.S.A.
- Pathology of mesoamerican nephropathy
Annika Wernerson, Stockholm, Sweden
- Proton pump inhibitors and kidney disease
Morgan Grams, Baltimore, U.S.A.
- Narcotic drugs
Speaker to be confirmed
• Variation in Pre-Dialysis nephrology care
- The changing pattern of kidney diseases at
dialysis onset
Vianda Stel, Amsterdam, The Netherlands
- Are we able to really slow progression in CKD?
Dick De Zeeuw, Groningen, The Netherlands
- The most prevalent one: Can we better handle
diabetics and delay dialysis?
Peter Rossing, Gentofte, Denmark
- How to avoid over- and underdiagnosis of
Chronic Kidney Disease
Marc E. De Broe, Antwerp, Belgium
• State of the art in Peritoneal Dialysis in 2017
Organised jointly with EuroPD
- Starting a patient on PD: troubleshooting the first
3 months
Miguel Perez Fontan, La Coruña, Spain
- Infectious problems in PD: from basic science to
the bedside
Martin Wilkie, Sheffield, United Kingdom
- Basic science in PD: translation for clinicians
(literature overview of major basic research in
the last years)
Achim Joerres, Cologne, Germany
- Transitions in ESRD: room for improvement?
Mark Lambie, Stoke-on-Trent, United Kingdom
• Geriatrics and rehabilitation of CKD patients –
what should the nephrologist know?
- Polypharmacy in elderly population with CKD how to deal with it
Aud Høieggen, Oslo, Norway
- CKD in the elderly - a growing epidemic or just a
matter of normal eGFR decline
Peter Barany, Stockholm, Sweden
- Anemia management in the elderly CKD patient
Francesco Locatelli, Lecco, Italy
- Dialysis in the elderly and frail patients
Angel Luis Martin de Francisco, Santander, Spain
• Quality of life in people with kidney disease
- What is quality of life, and how to measure it?
Friedo W. Dekker, Leiden, The Netherlands
- Ways to improve quality of life in clinical practice
Fergus Caskey, Bristol, United Kingdom
- The patient perspective on quality of life
Daniel Gallego-Azurro, Torrent (Valencia), Spain
- Using quality of life in benchmark initiatives
Francesca Tentori, Ann Arbor, U.S.A.
• Education in nephrology
Joint Session Renal Section and
Board of the UEMS & ERA-EDTA
- Introduction: The UEMS and ERA-EDTA
Alliance
Jorge B. Cannata-Andía, Oviedo, Spain
- The current status of European Nephrology
Education
Speaker to be confirmed
20
Madrid2017 Main Ann 1016.indd Sez1:20
4-11-2016 6:22:02
Preliminary Scientific Programme
Ethics
- Ethical aspects for programming animal studies
- Ethical aspects for programming clinical trials/
observational studies
- Ethics of biobanking and use of biological samples
- Ethics for the use of stem cell or manipulated
human cells
Special Interactive Session
Patient empowerment: an interactive “how to”
experience
- Pitfalls in patient-physician communication
- Shared decision making in true life
In this highly interactive workshop session method acting,
psycho-sociology and clinical patient encounters will be mix
to enhance understanding and knowledge of some major
problems when working with patients who take their care into
their own hands.
Special Session with European Medicines Agency
(EMA)
21
Madrid2017 Main Ann 1016.indd Sez1:21
4-11-2016 6:22:03
22
Madrid2017 Main Ann 1016.indd Sez1:22
4-11-2016 6:22:06
Submission of Abstracts
LANGUAGE
All abstracts must be written in English.
Communications should concern all aspects of
nephrology, the prevention and treatment of renal
diseases and associated conditions or the scientific
background to the study of the kidney.
HOW TO SUBMIT ABSTRACTS
Only submission through the congress website is
possible.
Abstracts sent by post or email will not be accepted.
You can send your abstracts from November 4, 2016.
Please go to the congress website www.era-edta2017.org
and follow the instructions for abstract submission.
All authors of correctly written and successfully
submitted abstracts will receive confirmation by e-mail.
Should you experience any unforeseen problems with
the electronic submission, please contact the ERA-EDTA
Operative Headquarters at [email protected].
GENERAL RULES
All abstracts must be submitted electronically through the
congress website www.era-edta2017.org.
All abstracts must be received by January 27, 2017
Abstracts received after this date cannot be considered
by the Paper Selection Committee.
CONFIRMATION
You will automatically receive an e-mail confirming
our receipt of your abstract.
Do not mail or fax your abstract
to the ERA-EDTA Operative Headquarters.
NOTIFICATION
The Presenting Author of each abstract accepted for
publication will be notified by April 5, 2017. If the
Presenting Author is unable to present the abstract,
another co-author can take his/her place. A letter from
the Presenting Author about the change is requested
and must be received by the ERA-EDTA Operative
Headquarters no later than April 20, 2017.
PUBLICATION
All abstracts accepted for presentation (either oral
or poster) will appear in NDT. Abstracts will appear
exactly as submitted.
Any abstract considered unsuitable for reproduction
will not be published.
LATE BREAKING CLINICAL TRIALS
The ERA-EDTA will consider abstracts related to
unpublished clinical trials for a special “Late breaking
clinical trials” session. The following trials will be
considered for evaluation if they comply with the
required characteristics:
- a prospective randomised intervention in renal
patients
(medications,
education,
dietetics,
physiotherapy, etc…), including at least 100 patients;
- a prospective observational study, including at least
500 patients;
- approved by an institutional ethical committee;
- not previously reported or published.
Abstracts may be accepted as oral communications or
posters, after regular evaluation by the review committee.
The LBCT abstracts can be submitted through the
congress website www.era-edta2017.org from March 6
to 27, 2017.
Abstracts which do not meet the criteria above will
not be considered for presentation.
WITHDRAWAL / CHANGES
Submitted abstracts cannot be withdrawn or changed.
No exceptions will be made.
CONTENT OF WORK AGREEMENT
The presenting author must confirm that all co-authors
agree with the submission and content of the work for
the 54th ERA-EDTA Congress. ERA-EDTA cannot be
deemed responsible for any infringement of this rule.
COPYRIGHT
By submitting the abstract, the author assigns copyright
to the ERA-EDTA.
ORIGINAL ABSTRACTS
Submitted abstracts must describe unpublished work
which is not already in press and which is not awaiting
possible acceptance by any other society that publishes
its proceedings.
Free Communications
The top scoring abstracts will be presented as free
communications, combined with mini lectures from
world-renowned scientists.
with the opportunity to have their posters printed and
delivered free of charge to the congress venue.
Moderated posters New!
A selection of posters will be discussed by the first
author and an expert moderator to cover the four main
topics (Basic Science, Clinical Nephrology, Dialysis,
Transplantation). Posters will be on display from 9.30
to 10.45 hrs on large plasma screens
Posters
There will be two poster sessions (June 4 and 5,
2017). Posters will be sorted by topic and will remain
on display from 7.30 to 17.00 hrs. Presenters will be
by their poster during the dedicated session time to
discuss their research with the visiting audience.
It will be possible to browse all posters online both
onsite and after the congress. Also this year, the ERAEDTA will be pleased to provide all poster presenters
Best posters New!
The best posters (sorted by main topic: Basic Science,
Clinical Nephrology, Dialysis, Transplantation) will be
on display on large plasma screens.
23
Madrid2017 Main Ann 1016.indd Sez1:23
4-11-2016 6:22:19
Travel Grants
We “ASQ” for your help for young nephrologists
in developing countries
ERA-EDTA has circulated an electronic feedback
questionnaire aimed at collecting impressions, suggestions and remarks among the delegates of the last
three Congresses, held in Amsterdam, London and
Vienna respectively.
Based on the final number of feedback questionnaires
completed, ERA-EDTA will offer congress grants to
young nephrologists living in low income countries
(GPD < USD 10,000) to attend the ERA-EDTA Congress in Madrid. The winners will be chosen among
those who have submitted an abstract which is then
accepted for presentation at Congress.
This initiative, named Altruistic Support by Questionnaire (ASQ), has become part of the exclusive ERAEDTA advantages for young nephrologists living in
disadvantaged areas of the world where education
and scientific updates are needed.
The Presenting Authors must be 45 years old, or
younger, by December 31, 2017.
To apply, please fill in the appropriate fields during the
abstract submission at www.era-edta2017.org.
Also this year the ERA-EDTA has decided to give up
to 90 travel grants to attend the Madrid Congress to
the best rated abstracts in the various categories. The
Presenting Authors must be 40 years old, or younger,
by December 31, 2017.
All awardees will receive:
a) Free congress membership;
b) A grant for EUR 500, except for the Presenting
Authors of the best abstracts of each category whose
grant will be of EUR 1,000.
The Presenting Authors of the two best abstracts of
each category, independently of age, will also receive
a diploma.
To apply, please fill in the appropriate fields during the
abstract submission at www.era-edta2017.org.
TRAVEL GRANT FOR THE BEST ABSTRACT ON
GERIATRIC NEPHROLOGY
Thanks to a generous grant from the International Society of Geriatric Nephrology and Urology (ISGNU),
meant to honour the memory of Prof. Dimitrious G.
Oreopoulos, ERA-EDTA will give a travel grant of
EUR 1,500 to the best abstract on geriatric nephrology
submitted by a young author (40 years old, or younger,
by December 31, 2017).
Abstracts can be related to all aspects of geriatric
nephrology and can be submitted under any of the
abstract categories.
To apply, please fill in the appropriate fields during the
abstract submission at www.era-edta2017.org.
IMPORTANT INFORMATION FOR YOUNG ABSTRACT AUTHORS
ERA-EDTA STANLEY SHALDON AWARD FOR
YOUNG INVESTIGATORS
If you are 40 years old or younger, and your abstract
is considered one of the best ones submitted to the
last three ERA-EDTA Congresses, you can win
the ERA-EDTA Stanley Shaldon Award for Young
Investigators.
The winner will receive the award during the Opening
Ceremony of the annual ERA-EDTA Congress.
The award consists in a special invitation to
participate in the ERA-EDTA Congress in which
the award is given; three years of ERA-EDTA
membership; an ex-officio position in the Young
Nephrologists’ Platform Board and a prize of EUR
10,000. Do not miss this unique opportunity to
submit your abstract to the ERA-EDTA!
For more information you can go to our website www.
eraedta.org (click on “About ERA-EDTA” and then
on “ERA-EDTA Awards”).
YOUNG NEPHROLOGISTS’ PLATFORM “FREE
MEMBERSHIP PROJECT”
A 1-year free ERA-EDTA membership will be
given, automatically, to the 30 young people who
have submitted an accepted abstract to an ERAEDTA Congress. Only young people (< 40 years of
age) who are already ERA-EDTA MEMBERS and
YNP MEMBERS can receive this free ERA-EDTA
membership. More information will be available
during the abstract submission procedure.
Abstract submission deadline: JANUARY 27, 2017
24
Madrid2017 Main Ann 1016.indd Sez1:24
4-11-2016 6:22:19
Abstract Categories
A)
B)
C)
D)
E)
F1)
F2)
G)
H)
I)
J1)
J2)
J3)
K1)
K2)
K3)
K4)
K5)
K6)
K7)
Acid-base and electrolytes
Cell signalling. Cell biology. Hormones
Renal development and cystic diseases
Genetic diseases and molecular genetics
Renal pathology. Experimental and clinical
Hypertension. Experimental
Hypertension. Clinical
Nephrolithiasis and uric acid
Clinical nephrology
Glomerulonephritis
AKI. Experimental
AKI. Epidemiology and outcome
AKI. Prevention and treatment
CKD. Lab methods, GFR measurement,
urine proteomics
CKD. Pathophysiology, progression and risk
factors
CKD. Clinical epidemiology
CKD. Anaemia
CKD. Bone disease
CKD. Nutrition, inflammation and oxidative stress
CKD. Rehabilitation
L1) Diabetes. Basic research
L2) Diabetes. Clinical studies
M1) Dialysis. Extracorporeal dialysis: techniques and
adequacy
M2) Dialysis. Peritoneal dialysis
M3) Dialysis. Cardiovascular complications
M4) Dialysis. Vascular access
M5) Dialysis. Anaemia
M6) Dialysis. Bone disease
M7) Dialysis. Epidemiology and outcome
M8) Dialysis. Health services research
M9) Dialysis. Protein energy wasting, inflammation
and oxidative stress
N1) Renal transplantation. Experimental, immunetolerance of allogenic and xenogenic transplants
N2) Renal transplantation. Epidemiology and outcome
N3) Renal transplantation. Treatment and
immunosuppression
O) Paediatric nephrology
P) History of nephrology
Q) Patient education research and training in
nephrology New!
25
Madrid2017 Main Ann 1016.indd Sez1:25
4-11-2016 6:22:19
26
Madrid2017 Main Ann 1016.indd Sez1:26
4-11-2016 6:22:21
Congress Information
LANGUAGE OF THE CONGRESS
The official language of the Congress is English. No
simultaneous translation will be provided. A CME Course
in Spanish (“Curso de Nefrologia”) will be organised please see page 19.
ADMISSION
Admission to the scientific sessions is strictly reserved to
registered congress members. Minors cannot access the
session halls even if accompanied by a registered adult.
The same applies also to the Exhibition.
ERA-EDTA as per the EFPIA HCP Code does not extend
hospitality in any way to persons other than the registered
congress members.
PRESS CENTRE
For accredited journalists only. Full press working facilities
and activities including press conferences, press releases
and services for press will be available at the IFEMA Feria
de Madrid - North Congress Center during the Congress
CERTIFICATE OF ATTENDANCE
The certificate of attendance will be sent to all regularly
registered delegates by email after the congress. In case
you do not receive it, please write to [email protected].
If you need a hard copy, you can collect it at the dedicated
desk located in the Registration Area of the IFEMA Feria
de Madrid - North Congress Center. Please notice that
the certificate will specify the exact number of days that
you will have attended the congress.
UEMS CME CREDITS
An application will be made to the European Accreditation
Council for Continuing Medical Education (EACCME) for
CME accreditation of the 54th ERA-EDTA Congress and
pre-congress CMEs. The EACCME is an institution of the
European Union of Medical Specialists (UEMS). Congress
members receiving certificates for ECMEC credits must
contact their National Accreditation Authority to have the
credits recognized (or converted) in their country of practice.
EACCME credits are recognized by the American Medical
Association (AMA) towards the Physician’s Recognition
Award (PRA). To convert EACCME credit to AMA PRA
category 1 credit, you should contact the AMA directly.
The total number of CME credits given to the ERA-EDTA
Madrid Congress will be posted on the website (www.
eraedta2017.org) as soon as they are available.
CME COURSES
Participation in the CME Courses on June 3, 2017 will
be on a “first come first served” basis. The courses are
reserved to regularly registered congress members and
are included in the registration fee.
In order to participate all regularly registered congress
members must go to the session halls and scan their badge
at the entrance (at participant’s own responsibility).
HOW TO RECEIVE UEMS CME CREDITS
ERA-EDTA will track attendance of congress members
during the congress in the IFEMA Feria de Madrid - North
Congress Center each day. Regularly registered congress
members must go to the session halls and scan their
badge at the entrance (at participant’s own responsibility).
Congress members will then be awarded the number of
credits towards the hours actually spent participating in the
sessions of the congress.
ERA-EDTA will send UEMS CME certificates to all regularly
registered participants by email approximately one month
after the end of the Congress. In case you do not receive it
by that time, please write to [email protected].
INSURANCE/LIABILITY
The ERA-EDTA is insured only to meet claims arising
from incidents caused by the organisers and their
equipment. Participants, exhibitors and visitors are
strongly recommended to be properly insured against
accidents they may suffer when travelling to and from
the Congress and during the Congress itself.
VENUE
IFEMA Feria de Madrid - North Congress Center
Avda. del Partenón, 5
28042 Madrid - Spain
www.ifema.es
Beware of Unofficial Websites!
Please be aware that there are unofficial websites that can
turn up in search engine results that offer housing and
registration for the 54th ERA-EDTA Congress but that are
no linked in any way to ERA-EDTA. Please make sure
to book your housing and congress membership only
through the official 54th ERA-EDTA Congress website at
www.era-edta2017.org!
27
Madrid2017 Main Ann 1016.indd Sez1:27
4-11-2016 6:22:42
Congress Membership Rules and Deadlines
CONGRESS MEMBERSHIP FEES AND DEADLINES
Early
From March 9 to
May 10, 2017
Late
From May 11
to June 6, 2017
Onsite
EUR 300.00
EUR 430.00
EUR 450.00
EUR 500.00
EUR 600.00
EUR 650.00
Within March 8, 2017
Status
ERA-EDTA MEMBER
(individual and regular group)
ERA-EDTA NON MEMBER
(individual and regular group)
STUDENT/TRAINEE*
(only onsite registration)
LOCAL STUDENT*
(only onsite registration)
NURSE/DIETICIAN ** New!
EUR 300.00
EUR 60.00
EUR 100.00 (1 day- June 3)
EUR 160.00 (1 day)
1-2 DAYS ERA-EDTA MEMBER ***
EUR 290.00 (2 days)
EUR 200.00 (1 day)
1-2 DAYS NON MEMBER
BLANK GROUP****
EUR 370.00 (2 days)
EUR 460.00
# IMPORTANT: Please note that congress members submitting and
paying their congress membership fee as non ERA-EDTA members will
not be entitled to reimbursement if, at a later stage, they become ERAEDTA members or if, despite being active ERA-EDTA members they
incorrectly register as non ERA-EDTA members.
Once the registration has been processed it cannot be changed or
reimbursed.
*Student/trainee congress memberships (35 years old or younger, the birth year
must not be earlier than 1982). Online registrations available from May 11
to June 1, 2017. From June 2, 2017 you can register only at the IFEMA
Feria de Madrid - North Congress Center. These types of registration
cannot be sponsored by a company/agency/institution etc. During
the online procedure you must upload a photocopy of your picture ID
(passport, identity card, driving license with birth date), a photocopy of
your original student’s card (for students) and a signed letter from your
mentor/university to prove your status. ERA-EDTA reserves the right
to verify all declarations. If you make the registration onsite in Madrid
you must hand over the documents above to the hostess.
*Local student congress memberships (28 years old or younger, the birth year
must not be earlier than 1989 – only for students living in Spain). The same
rules above apply.
** Nurse/Dietician congress memberships are available online from May 11
to June 1, 2017. From June 2, 2017 you can register only at the IFEMA
Feria de Madrid - North Congress Center. This exceptionally low
congress membership fee is reserved for nurses/dieticians and only
for the participation to the sessions on June 3, 2017. During the online
procedure you must upload a signed letter of your hospital to prove
your status. If you make the registration onsite in Madrid you must
hand over the document above to the hostess. ERA-EDTA reserves the
right to verify all declarations.
HOW TO REGISTER
All registrations must be submitted through the Congress
website www.era-edta2017.org
ERA-EDTA MEMBERSHIP INFORMATION
New applicants and members with outstanding
membership fees, wishing to sign up/pay for ERAEDTA membership in order to benefit from the reduced
congress membership fee, must apply for membership,
or pay the outstanding fees, no later than 10 working
days prior to the respective registration deadlines.
***1-2 Days congress memberships are available online from May 11 till
June 6, 2017. You can register online also during the congress or at the
IFEMA Feria de Madrid - North Congress Center, from June 2, 2017.
This type of registration entitles admission to the session and poster
and exhibition halls only on the date mentioned on the congress badge.
It is also possible to make two one-day registrations if you are able to
attend the congress for two days (consecutive or not).
****Blank group congress memberships (minimum of 10 and more delegates):
bookings and payments must be received by the early deadline of March
8, 2017. The final list of names must be submitted by May 18, 2017.
METHOD OF PAYMENT
Until May 22, 2017: credit card (Visa, MasterCard and
American Express) and bank transfer.
Please check the website www.era-edta2017.org
for full information on the congress membership rules
From May 23 to June 6, 2017: credit card (Visa,
MasterCard and American Express). Payments made
by bank transfer or cheque will not be accepted.
Beware of Unofficial Websites!
Please be aware that there are unofficial websites that
can turn up in search engine results that offer housing
and registration for the 54th ERA-EDTA Congress
but that are no linked in any way to ERA-EDTA.
Please make sure to book your housing and congress
membership only through the official 54th ERA-EDTA
Congress website at www.era-edta2017.org!
Cash (EUR only) will be accepted only from June 2 to
6, 2017.
CANCELLATION POLICY
Before May 11, 2017
After May 11, 2017
75% of the amount paid,
No refund
net of bank charges.
of the amount paid.
All reimbursements will be done after the congress.
28
Madrid2017 Main Ann 1016.indd Sez1:28
4-11-2016 6:22:43
be globalċ be oneċ
oneworld®ƫis proud to be your
official airline allianceċ
The oneworld network covers
more than āČĀĀĀ destinations in
āĆĀ plus countriesČ so we can get
you anywhere you need to beċ
Learn more at oneworldċcom
an alliance of the world's leading airlines working as oneċ
airberlin American Airlines British Airways Cathay Pacific Finnair Iberia Japan Airlines LATAM
Malaysia Airlines Qantas Qatar Airways Royal Jordanian SĈ Airlines SriLankan Airlines
oneworld benefits are available only to passengers on scheduled flights that are both marketed and operated by a oneworld member airline (marketed
means that there must be a oneworld member airlineĚs flight number on your ticket)ċ For information on oneworldČ visit wwwċoneworldċcomċ airberlinČ
American AirlinesČ British AirwaysČ Cathay PacificČ FinnairČ IberiaČ Japan AirlinesČ LATAM AirlinesČ Malaysia AirlinesČ QantasČ Qatar AirwaysČ Royal JordanianČ
SĈ AirlinesČ SriLankan Airlines and oneworld are trademarks of their respective companiesċ LATAM Airlines (Paraguay) is currently not a part of oneworldċ
Madrid2017 Main Ann 1016.indd Sez1:29
4-11-2016 6:22:49
About
CONGRESS CITY
Madrid is iin the top 5 cities hosting most congresses
in the world
worl – for the fourth consecutive year - and
congress destination in Spain, with 7.5% more
the top con
events than in 2013. This past year, the capital held
14,282 mee
meetings among which 2,236 congresses and
3,860 conve
conventions, leading to 1,121,225 participants
coming to M
Madrid for business.
Xxxxxxxxxxxxxxxxx
TRAVEL TO MADRID
Madrid is connected by air to the main European and
American cities, and by road and train to all Spanish
cities. Due to our cultural connection with Latin
America, Madrid is also the main entrance from this
area of the world into Spain.
By air
Madrid’s Adolfo Suárez Madrid-Barajas airport is one
of Europe’s largest airports, with connections to both
national and international destinations offering direct
flights to 69 different countries and 177 cities all over
the world. The capital is in fact only two hours from
Berlin, London, Paris and Rome, and seven hours from
New York, Mexico City and Caracas. More than 50
million passengers pass through here every year.
TRANSFERS FROM/TO AIRPORT
Madrid is the capital of Spain, a modern metropolitan
city considered to be the economical and industrial
centre of Spain, also thanks to its location in the centre
of the Iberian Peninsula. Narrow, cobbled streets
leading to bustling squares and breath-taking historical
architecture hidden around every corner maintain the
city’s quaint and Spanish vibe, yet its new metropolitan
infrastructure and modern enhancements really
represent Madrid’s present, and future, as Spain’s most
important city. Madrid is also one of the greenest cities
in Spain: its network of parks and tree-lined avenues
make it a great city for running or simply to spend a
day outside. Did we forget to mention that it has been
considered as the second safest European capital?
Madrid really has it all!
By bus
Direct connection from the airport to the city centre is
provided by the Express shuttle service, which operates
24 hours a day. It runs every 15-20 minutes during the
day and every 35 minutes at night, completing the
journey in about 40 minutes. The Express Bus makes
only two stops: O’Donnell and Atocha Station (Plaza
de Cibeles at night, from 23.30 hrs).
Single tickets: EUR 5.00; purchased on board.
By metro
The airport can be reached also by metro, taking Line 8
that connects all terminals with the city. The Congress
Venue (IFEMA Feria de Madrid – North Congress Center)
is also well connected with both the airport and the city
through Line 8 (Metro stop: Campo de las Naciones).
Single Metro ticket: EUR 4.50 - EUR 5.00 (according to
the starting point).
Tickets can be purchased at ticket offices/automatic
tickets machines in each metro station.
By taxi
Journey time from the airport to the centre is
approximately 30 minutes.
Prices follow fixed airport rates of EUR 30.00 between
the airport and the inner M30 area (*).
If final destination is out of this area, the taximeter will
count at the corresponding tariff rate.
(*) M30 area: all the city centre and financial area. Please
note, however, that IFEMA Feria de Madrid – North
Congress Center (Congress Venue) is out of this area.
By Light Train (Cercanias)
Connections from the airport are also provided by the
“light” train Cercanias, which will lead you to the city
centre in less than half an hour.
Ticket from the airport to: Atocha Train Station;
Chamartin Train Station; Nuevos Ministerios; Sol and
Mendéz Álvaro.
Price per ticket: EUR 2.60 – Free for AVE (fast speed
train) users.
Tickets can be purchased at ticket offices/automatic
tickets machines in each station.
VIBRANT CITY
Cutting-edge facilities, devoted professionals and
modern infrastructures: Madrid is much more than
the political and financial capital of Spain. Filled with
charming sidewalk cafés, restaurants, vanguard bars
and nightclubs, Madrid is surely the city that never
sleeps. The capital may have more bars than any other
city on earth that together with festivals or annual
events, provide you with a vast choice on what to do
during your evenings. Madrid is also one of the most
open cities on earth and it doesn’t matter where you’re
from for the often heard phrase to ring true: ‘If you’re
in Madrid, you’re from Madrid’.
CULTURAL CITY
Madrid has nearly one hundred museums and more
than two thousand historical and artistic monuments
that witness the presence and achievements of all the
peoples who made history here in the capital. For
centuries, Spanish royals showered praise and riches
upon the finest artists of the day, from home-grown
talents such as Goya and Velázquez to Flemish and
Italian giants. The city has a lot to offer in terms of
cultural experience: among the major museums, there
are the Museo del Prado (with almost 10,000 works of
art housed here), Centro de Arte Reina Sofía and Museo
Thyssen-Bornemisza.
30
Madrid2017 Main Ann 1016.indd Sez1:30
4-11-2016 6:22:50
TRAVEL IN MADRID
Xxxxxxxxxxxxxxxxx
Madrid has some of the most thorough and leastexpensive public transit in Europe: buses and metro run
regularly during the day and are a quick, convenient
and cheap way to travel around the city.
By bus
EMT public buses run from approximately 6.00 to 23.00
hrs from Monday to Friday, whereas during weekends
service begins around 7.00 until 23.00 hrs. Running
times vary according to the bus route but the average
frequency of the service is between 15 and 20 minutes
in weekdays.
BUS/METRO Single tickets: EUR 1.50 - EUR 2.00;
BUS/METRO 10 Ticket pass: EUR 12.20 (Zone A).
Tickets can be purchased directly on the bus or at
ticket offices/automatic tickets machines in each metro
station.
Website: www.emtmadrid.es/index.aspx
ESSENTIAL INFORMATION
Currency
The Euro is the official currency of Spain (€/EUR).
Visa, MasterCard and other credit cards are widely
accepted.
Climate
Hemingway once said that Madrid has Spain’s best
climate. With a dry climate and little rainfall, the city
has a typical Mediterranean climate with hot summers
and cold winters. Due to Madrid’s high altitude of 600650 meters, the most pleasant warm weather starts from
May when temperatures become almost summery.
Around June, average temperatures are about 20-25ºC
(70-75ºF).
By metro
Madrid’s underground system is the second largest
European metro network (after London), with 293 km
of lines and 300 stations that cover most of the city.
There are twelve lines that generally operate from 6.00
to 2.00 hrs Monday to Saturday, with reduced operating
hours on Sundays.
BUS/METRO Single tickets: EUR 1.50 - EUR 2.00;
BUS/METRO 10 Ticket pass: EUR 12.20 (Zone A).
Tickets can be purchased at ticket offices/automatic
tickets machines in each metro station.
Website: www.emtmadrid.es/index.aspx
Language
The mother tongue of Spain is Spanish and the most
commonly spoken foreign language is English,
followed by French.
Electricity
Spain’s standard electricity supply is 220 Volts (V),
50 Hertz (Hz) AC. Plugs and sockets are European
standard with 2 round pins.
By light train
An alternative to the bus or metro are RENFE Cercanias
(suburban passenger service) that run from 5.00-6.00 to
midnight (approx.) and offer frequent daily services to
places of interest for tourists such as Alcalá de Henares,
El Escorial and Aranjuez.
Single tickets: EUR 1.70.
Tickets can be purchased at ticket offices/automatic
tickets machines in each station.
Mobile phone coverage
Spain uses the GSM international coverage standard.
American frequency ranges (850 and 1900 MHz) are
different from those in Europe (900 and 1800 MHz),
but the widespread use of 3G and 4G devices
provides support for the entire range of bands in both
continents.
Shopping
From exclusive international boutiques to alternative
outlets and traditional shops, when it comes to
shopping options, Madrid has everything you may
need. Opening hours are normally from 9.00-10.00 am
till 20.00-22.00 hrs. Most of the shops do not close over
lunch, except for those far from the city centre that do
close from 14.00 to 16.00-17.00 hrs. Each quarter has its
own unique shops that differ in style and designs; main
shopping areas are without any doubts Gran Vía, in the
touristic area, and Serrano, for luxury shopping. Here,
shops open even on Sunday and bank holidays.
Time Zone
Madrid is located in the Central European time zone
(CET = GMT / UCT + 1). From the last Sunday in
March to the last Sunday in October, summer time is
in effect (MESZ).
Tourist Information
For info on sightseeing, tips for dining, shopping,
cultural events please visit the official Madrid tourist
guide www.esmadrid.com/en.
Once on site, if you want to receive more information
you can stop by the Official Tourist Center located in
Plaza Mayor, 27 open Monday to Sunday from 9.30 to
20:30 hrs.
31
Madrid2017 Main Ann 1016.indd Sez1:31
4-11-2016 6:22:53
Passport and Visa Information
VISA/INVITATION LETTER
An invitation letter for visa purposes can be obtained
through the ERA-EDTA 54th Congress website www.eraedta2017.org (first option). Should this not be sufficient,
the Visa secretariat will be pleased to send, upon request,
a personal invitation to all participants (second option).
This letter should NOT be considered as an offer of any
kind of financial support on behalf of the organizers. An
official invitation letter can be requested by email to the
President of the Congress Prof. Jorge B. Cannata-Andía
([email protected]) at least three months in advance
(third option). This letter however does NOT involve any
commitments by the Congress Organizers to cover fees,
accommodation, travel expenses or other costs connected
to the participation in the Congress. ERA-EDTA will
not be held responsible for visas that are not granted.
International registrants, who require a letter of invitation,
will first need to complete the online registration for the
54th ERA-EDTA Congress (check www.era-edta2017.
org, section “Registrations”). Letters of invitation for
spouse/guest registrants will only be provided if the
accompanying individual has completed his or her
congress registration.
Thailand, The Gambia, Togo, Tunisia, Turkmenistan,
Turkey, Uganda, Ukraine, Uzbekistan, Vietnam, Yemen,
Zambia, Zimbabwe).
Citizens of these countries can also travel to Spain if
they have a residence permit or a long-term visa issued
by another country in the European Union (with the
exception of the United Kingdom, Ireland, Romania,
Bulgaria and Cyprus), Switzerland, Norway, Iceland and
Lichtenstein.
Citizens of all other countries must be in possession of
documents which justify the object and the conditions
of their stay, and be in possession of sufficient economic
resources for their maintenance throughout the period
they are intending to remain in Spain. The documents
they are required to present will vary according to the
reason of the trip. You can check these on the website of
the Ministry of Foreign Affairs and Cooperation (www.
exteriores.gob.es).
It is advisable to purchase travel insurance for your trip.
Given that conditions may vary, we suggest that you
contact the Spanish Embassy or Consulate in your country
to verify these requirements before you plan your trip.
APPLICATIONS FOR SHORT TERM VISAS
(Tourism, private, business, conference)
All visa applicants must apply at the Spanish Embassy or
Consulate in person.
Those who do not require a visa
If you are a citizen of the EU, Switzerland, Norway,
Iceland or Liechtenstein you will need a valid passport
or ID card. Additionally, in the case of a minor travelling
with an ID document, this must be accompanied by
written permission from the parents.
IMPORTANT NOTES
Applications cannot be submitted more than three
months prior to departure. However please present your
application at least two months before the intended travel.
The consular fees have to be paid when submitting the
application; these fees are not reimbursed in case of visa
refusal. All points of the visa application form have to be
filled in completely and must be correct. If documents are
missing, this may cause inadmissibility of the application
or delay with the application.
Those who need a visa
The maximum stay in Spain is 90 days. There are a number
of countries whose citizens are required to have a valid
current visa in order to enter Spain (Afghanistan, Algeria,
Angola, Armenia, Azerbaijan, Bahrain, Bangladesh,
Belarus, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina
Faso, Burundi, Cabo Verde, Cambodia, Cameroon,
Central African Republic, Chad, China, Comoros, Congo,
Cuba, Democratic Republic of the Congo, Djibouti,
Dominican Republic, Ecuador, Egypt, Equatorial Guinea,
Eritrea, Ethiopia, Fiji, Gabon, Georgia, Ghana, Guinea,
Guinea-Bissau, Guyana, Haiti, India, Indonesia, Iran,
Iraq, Ivory Coast, Jamaica, Jordan, Kazakhstan, Kenya,
Kuwait, Kyrgyzstan, Laos, Lebanon, Lesotho, Liberia,
Libya, Madagascar, Malawi, Maldives, Mali, Mauritania,
Mongolia, Morocco, Mozambique, Myanmar, Namibia,
Nepal, Niger, Nigeria, North Korea, Oman, Pakistan,
Papua New Guinea, Philippines, Qatar, Russia, Rwanda,
São Tomé and Principe, Saudi Arabia, Senegal, Sierra
Leone, Somalia, South Africa, South Sudan, Sri Lanka,
Sudan, Suriname, Swaziland, Syria, Tajikistan, Tanzania,
32
Madrid2017 Main Ann 1016.indd Sez1:32
4-11-2016 6:22:57
Hotel Accommodation
Group Reservations
For Group Bookings with five or more rooms, please
contact AIM Group International – AIM Spain at
[email protected] directly and send us
your detailed request: the number of rooms required, the
arrival and departure dates, the preferred hotel or area.
An offer based on your requirements will be provided at
soon as possible. Alternatively, please feel free to contact
us anytime at the above telephone number.
AIM Group International – AIM Spain has been appointed
as the Official Housing Bureau of the 54th ERA-EDTA
Congress. Room blocks at special rates are being held in
several hotels of various categories and located in three
main areas of the city: close to the congress venue, the
financial area and the old town. All of them guarantee
good connections to the congress venue.
AIM Group International – AIM Spain
Phone: +34-91-2873400
e-mail: [email protected]
Individual Reservations
Individual hotel bookings can be done online on the
Congress website www.era-edta2017.org (section “Hotel
Accommodation”). Here, you are prompted to insert
your personal details (an email will be sent automatically
to confirm your booking) and hotel preferences. After
completing the hotel booking, the applicant will receive
a system notification that the reservation request was
received (this is not a confirmation of the room). As soon as
possible, you will receive a formal confirmation regarding
your accommodation. Confirmation of the hotel booking
will be issued only after the prepayment is received. Full
prepayment is required to guarantee the room.
Changes and cancellations must be made in writing to
AIM Group International – AIM Spain; the hotels will not
accept direct changes and/or cancellations. A handling fee
of EUR 30.00 will be charged for all reservation changes.
A full hotel list, inclusive of rates, hotel maps and all the
relevant information is available on the Congress website
www.era-edta2017.org (section “Hotel Accommodation”).
Please note that availability in some of the hotels may be
limited. Rooms are being allocated on a first come, first serve
basis. Early reservation is therefore highly recommended.
Room rates are indicated in Euro (EUR) per room/per
night inclusive of breakfast and Spanish VAT (Currently
10%). VAT is subject to change and as a result room rates
may increase without prior notice, in line with any change
in applicable tax.
Beware of Unofficial Websites!
Please be aware that there are unofficial websites that
can turn up in search engine results that offer housing
and registration for the 54th ERA-EDTA Congress
but that are no linked in any way to ERA-EDTA.
Please make sure to book your housing and congress
membership only through the official 54th ERA-EDTA
Congress website at www.era-edta2017.org!
Child Care
AIM Spain is available to give you a quote for babysitting
service, since, as clearly written in the announcement,
it is strictly forbidden to have children in any of the
Congress Center premises during the meeting. Please do
not hesitate to contact AIM Spain for a quote (phone: +34
91 2873400, e-mail: [email protected]).
33
Madrid2017 Main Ann 1016.indd Sez1:33
4-11-2016 6:22:58
Hotel List
NAME OF THE HOTEL
SUGGESTED PUBLIC
TRANSPORT
CAT. AREA
DISTANCE WITH PUBLIC
TRANSPORT (MINUTES)
AC AITANA
4
Financial District
Metro line 10 + line 8
28 min.
AC CUZCO
4
Financial District
Metro line 10 + line 8
25 min.
AC MADRID FERIA
4
Congress Area
Free Shuttle service
10 min.
AXOR BARAJAS
4
Congress Area
Free Shuttle service
15-20 min.
AXOR FERIA
4
Congress Area
Free Shuttle service
15-20 min.
AYRE GRAN HOTEL COLÓN
4
Other Areas
Metro line 6 + line 8
35 min.
COURTYARD MADRID PRINCESA
4
City Center
Metro line 6 + line 8
35 min.
EXE PUERTA CASTILLA
4
Financial District
Metro line 10 + line 8
26 min.
H10 TRIBECA
4
Financial District
Metro line 10 + line 8
28 min.
HILTON MADRID AIRPORT
4
Congress Area
Bus line 112
42 min.
HOLIDAY INN CALLE ALCALA
4
Congress Area
Bus line 104
40 min.
ILUNION ALCALÁ NORTE
4
Congress Area
Bus line 104
40 min.
MADRID MARRIOT AUDITORIUM
4
Congress Area
Free Shuttle service
25 min.
MELIA AVENIDA AMERICA
4
Congress Area
Free Shuttle service
12 min
MELIA CASTILLA
4
Financial District
Metro line 10 + line 8
30 min.
MELIÁ GALGOS
4
Financial District
Metro line 10 + line 8
30 min.
NH ALONSO MARTINEZ
3
City Center
Metro line 10 + line 8
27 min.
NH BALBOA
3
City Center
Metro line 6/9+ line 8
35 min.
NH BARAJAS
3
Congress Area
Bus line 112
45 min.
NH COLLECTION COLÒN
4
City Center
Metro line 4 + line 8
37 min
NH COLLECTION EUROBUILDING
4
Financial District
Metro line 10 + line 8
27 min.
NH HESPERIA MADRID
5
City Center
Metro line 10 + line 8
25 min.
NH NACIONAL
4
City Center
Cercanias + metro line 8
32 min.
NH VENTAS
4
Other Areas
Metro line 6 + line 8
40 min
NH ZURBANO
4
City Center
Metro line 10 + line 8
25 min.
NOVOTEL CAMPO DE LAS NACIONES
4
Congress Area
Walking Distance
3 min.
PULMAN MADRID AIRPORT & FERIA
4
Congress Area
Walking Distance
3 min.
RAFAELHOTELES ATOCHA
4
City Center
Cercanias + metro line 8
35 min.
SILKEN PUERTA AMERICA
5
City Center
Metro line 6 + line 8
35 min.
SILKEN PUERTA MADRID
4
Congress Area
Free Shuttle service
15 min.
SILKEN TORRE GARDEN
3
Other Areas
Bus line 104 + line 70
50 min.
VINCCI SOHO
4
City Center
Cercanias + metro line 8
32 min.
VINCCI SOMA
4
City Center
Metro line 4 + line 8
35 min
YOU WILL FIND THE COMPLETE AND UPDATED LIST OF AVAILABLE HOTELS, AS
WELL AS A HOTEL MAP, ON THE CONGRESS WEBSITE WWW.ERA-EDTA2017.ORG
(UNDER THE SECTION “HOTEL ACCOMMODATION”).
34
Madrid2017 Main Ann 1016.indd Sez1:34
4-11-2016 10:59:24
Important Deadlines
ABSTRACTS
Abstract submission: January 27, 2017
Travel grant application: January 27, 2017
LBCT abstract submission: March 27, 2017
Notification of abstract acceptance/rejection: April 5, 2017
REGISTRATIONS
Early: March 8, 2017
Blank (groups only) - Booking and prepayment: March 8, 2017
Late: May 10, 2017
Blank (groups only) - Name list: May 18, 2017
Onsite:
May
O
nsite: ffrom
rom M
ay 11
11 to
to June
June 6,
6, 2017
2017
35
Madrid2017 Main Ann 1016.indd Sez1:35
4-11-2016 6:23:04
Next ERA-EDTA Congresses
56
ERA-EDTA
th
Congress
Budapest, Hungary
2019 May 23
rd
– 26th
36
Madrid2017 Main Ann 1016.indd Sez1:36
4-11-2016 6:23:08
ENP vo
All about Nephrology
This new
European Nephrology
Portal, or in short, ENP,
will enable Nephrologists and
renal healthcare professionals
to connect with the world
of kidney and
kidney health
All in one place
ENP
the online hub
for the whole Nephrology community!
ALL
ERA-EDTA’s
scientiǤc content
CME Courses
C
N
DT
NDT-EDU
articles
LLeaders
eade in Nephrology
+ 6600 congress
pr
presentations
News/Hot Topics
EuroPD videos
& editorials!
37
ENP
volantino
A4 Ann
0615.indd
1 Sez1:37
Madrid2017
Main
1016.indd
08/05/166:38:24
09.47
4-11-2016
ERA-EDTA is a medical association active in encouraging
iinter
intercultural
ntercult
nte
nter
c ural
al com
co
communication
munication and
and knowledge
know edge
knowl
g
What can ERA-EDTA
!"#$%"&""'(
! "#$%"&"" '( !
!%)*"+$*&'(
%)*"+$*& '(
,-%!-%.
+"%+
,-
% !- % . +"%+
/!/ !01!/
-2
do for you?
53 Congress
ERA-EDTA
rd
ViAustri
ennaa
Held join
jointly
joi
oin
in with
with
ih
ERA-EDTA members are entitled
t
to EXCLUSIVE benefits:
t Free subscription to NDT and CKJ and access to NDT archive
t Exclusive access to scientific and educational contents
t Very special low registration fee at the ERA-EDTA Congress
t Special access to the ERA-EDTA restricted libraries on the web-site
t Special Discounts to Oxford Universityy Press Medical publications
www
era-edta2016.org
EUROPEAN
RENAL
NUTRITION
What can you
do
for ERA-EDTA?
Become a member
and start to network
now!
www.era-edta.org
Ac
Actively
be part of the largest and
mos
most important Nephrological
Society in Europe.
ER
ERA-EDTA
started its Fellowship
Prog
Programme in 2006. Up to now,
more than 180 fellowships have been
granted.
ckj
FEES
WAIVED
IN 2016
NOW FULLY
ACCESS
OPEN ACCESS
ISSN 0931-0509 (Print) ISSN 1460-2385 (Online)
Volume 31 Number 3 March 2016
Re
Receive
its journals ndt (Nephrology Dialysis Transplantation – impact
factor 4.085) and ckj (Clinical Kidney
Journal - open access), the most important nephrological journals in Europe.
ckj.oxfordjournals.org
urrnalls.org
ndt
NEPHROLOGY DIALYSIS TRANSPLANTATION
Basic and clinical renal science
Strauss monument, Stadtpark Vienna
53rd ERA-EDTA Congress, Vienna,
Austria, 21-24 May 2016
www.ndt.oxfordjournals.org
Participate in its annual congresses, major events attended by nephrologists
from all over the world. More than 8,000
delegates participated in the last ERAEDTA Congress (Vienna, Austria - May
21-24, 2016). ERA-EDTA members can
take advantage of extremely low
early preregistration fees.
Scan
Scan to
to view
view this
this journal
journal
on
on your
your mobile
mobile device
device
Th ERA-EDTA Research ProThe
gram is an initiative launched in
gramme
2009, 3 calls took place till now. Should
you wish to know which projects have
been granted from 2009, please visit
the Research Programme section of our
website www.era-edta.org.
ERA-EDTA has a diverse programme
ER
of CCME Courses throughout Europe.
In 2016, 22 events have been organised
in many different countries. ERA-EDTA
members receive free access to a
selection of these presentations directly
online.
The ER A - ED TA R e g i s t r y (www.
Th
era
era-edta-reg.org) collects, analyses,
distributes, reports data on renal replacement
therapy in Europe, at congresses, on journals
and on a dedicated website. It also teaches
CMEs and trains fellows.
ERBP (European Renal Best Practice - www.europeanren
renal-best-practice.org) defines the future of Euro
ropean nephrology guidance by improving the
ooutcome of patients with kidney disease in a susta
tainable way through enhancing the availability
o knowledge.
of
pag.
ERA-EDTA
x main
ann Madrid2017.indd
1-2
Madrid2017
MainA3
Ann
1016.indd
Sez1:38
4-11-2016 6:38:27
ERA-EDTA for You
Joint scientific
symposia
Co-hosted by the
European Renal Association-European Dialysis and Transplant
Association, The Lancet, and The Lancet Diabetes & Endocrinology
C
Close
collaboration bet
tw
tween
ERA-EDTA and “The
Lancet” and “The Lancet Diabetes & Endocrinology”. Issues of
both journals were devoted to
kidney diseases and were published in conjunction with the
ERA-EDTA Congresses in Amsterdam (2014), London (2015)
and Vienna (2016). Special sessions have been
organised jointly at the last three meetings. The
collaboration has been confirmed for 2017 with a
special renal issue scheduled for June 2017 and a
symposium at the ERA-EDTA Congress in Madrid.
52nd ERA-EDTA Congress 2015,
ExCeL Centre, Room N11,
London, UK.
52nd ERA-EDTA Congress 2015,
ExCeL Centre, Room N11,
London, UK.
Friday May 29, 2015:
3.15–4.45pm.
Saturday May 30, 2015:
11.45am–1.15pm.
Research – Chairs:
Sarah Linklater & Markus Ketteler.
Reviews – Chairs:
Philippa Berman & Denis Fouque.
THE LANCET® is a registered trademark of Reed Elsevier Properties SA, used under licence.
T ERA-EDTA initiatives for
The
yyoung nephrologists include
a number of grants of various
kinds: travel grants to present free
communications or posters at the
annual congress, travel grants to
attend CME Courses, further grants
assigned through the National
Societies of Nephrology based in
European countries, as well as long
or short term fellowships (see point 5).
ERA EDTA cooperates
ERA-EDTA
t with
ith other
th major
j SSocieties
i ti off
p
Nephrology
and other medical specialties: special
ER
ERA-EDTA
sessions are organized at the ASN,
EESPN, ESC, JSN, ESOT, EuroPD, ISPD, etc.
An inter-disciplinary approach established to disseminate
knowledge and information amongst those interested
in dialysis, transplantation and renal diseases
E\WKLVFHUWLÀFDWHZDUUDQWVWKDW
Ruth Pepper
LVDZDUGHGE\WKH
3DSHU6HOHFWLRQ&RPPLWWHHRIWKH$VVRFLDWLRQ
IRUWKHRXWVWDQGLQJVFLHQWLÀFSUHVHQWDWLRQ
THE ASSOCIATION OF SERUM CALPROTECTIN (S100A8/A9) LEVELS WITH DISEASE RELAPSE
IN PR3-ANCA ASSOCIATED VASCULITIS
5XWK3HSSHU-XOLDQD'UDLEH,PPXQH7ROHUDQFH1HWZRUN-RKQ6WRQH8OULFK6SHFNV3HWHU0HUNHO4$ODQ6DODPD5$9(,QYHVWLJDWRUV
8&/&HQWUHIRU1HSKURORJ\/RQGRQ8QLWHG.LQJGRP+DUYDUG0HGLFDO6FKRRO&OLQLFDO5KHXPDWRORJ\%RVWRQ0$
0D\R&OLQLF0HGLFLQH5RFKHVWHU0148QLYHUVLW\RI3HQQV\OYDQLD'LYLVLRQRI5KHXPDWRORJ\3KLODGHOSKLD3$
*LYHQDWWKHQG&RQJUHVV
$QGU]HM:LHFHN
(5$('7$3UHVLGHQW
TThe Young Nephrologists’ Platform (YNP)
a
aim
aims
to involve young nephrologists in all
ERA-E
ERA-EDTA
activities and to help
m
YNP members
in their career.
o YNP’s many successful
One of
activit
activities
is the YNP Advisory
Progra
Program.
Madrid2017 Main Ann 1016.indd Sez1:39
Th new European Nephrology Portal (ENP)
The
ena
enables Nephrologists and renal healthcare
professionals to connect with the world of
kidney and kidney health. In addition to Congress
E-materials users will find selected Industry
Symposia presentations, key publications from
NDT-Educational, ERA-EDTA working groups,
CME courses, EuroPD CMEs and the ERAEDTA’s Young Nephrologist program. News in
Nephrology, Hot topics, Leaders in Nephrology
and Literature Review complete the ENP content.
Discover it here www.enp-era-edta.org.
/RQGRQ8QLWHG.LQJGRP0D\
-RQDWKDQ)R[
(5$('7$6HFUHWDU\7UHDVXUHU
ERA-EDTA has created specific
Working Groups to encourage
e
research, communication of knowledge,
teaching and to participate in education programmes.
All Working Groups organise cutting-edge CME
courses related to their research field(s).
ERA-EDTA gives more than 1,200 free online
subscriptions to ndt and ckj to developing
countries all over the world through the HINARI
pro
programme;
furthermore members living in
ddeveloping countries all over the world pay
aan extremely low annual membership fee.
2-11-2016
4-11-2016 12:42:55
6:38:33
Oxford University Press Book Club
Exclusive
35%
discount for
ERA-EDTA
members
visit http://www.oup.com/uk/sale/eraedta
Madrid2017 Main Ann 1016.indd Sez1:40
4-11-2016 6:38:36
Brochur
W
ERA-EDTA
As a member you will become part of one of
the most influential European Medical Associations!
ISSN 0931-0509 (Print) ISSN 1460-2385 (Online)
Volume 31 Number 3 March 2016
ndt
Check out all the benefits:
NEPHROLOGY DIALYSIS TRANSPLANTATION
Basic and clinical renal science
Strauss monument, Stadtpark Vienna
53rd ERA-EDTA Congress, Vienna,
Austria, 21-24 May 2016
www.ndt.oxfordjournals.org
Scan
Scan to
to view
view this
this journal
journal
on
on your
your mobile
mobile device
device
ard”,
ing forw
tiz,, “Mov
Ortiz
ina Ort
Crist
ique,
d techn
, mixe
2014
120
cm x
70 cm,
from
ition
the exhib
ns”
iratio
“Asp
2:
2:27
4 6:2
201
28-10-
dd
7.in
Madrid
1
201
• NDT (Nephrology Dialysis Transplantation) subscription,
including exclusive access to the archives.
• Full access to the presentations of the ERA-EDTA supported
CME Courses.
• Possibility to organize ERA-EDTA supported CME Courses.
• Active participation in the decision making policies
of the Association.
• Special discounted congress membership fees.
• Special discounts (35%) on the purchase fees
of Oxford University Press (OUP) books.
• Participation in the Young Nephrologists’ Platform (YNP),
if you are less than 40 years old.
• Take advantage of special membership fees for low income
countries.
• Unlimited access to ERA-EDTA Congress E-materials,
for all ERA-EDTA members who participate at the Congress.
•E
Exclusive free access to EuroPD videos.
• SSpecial discounted membership fees for young members.
•N
New! Special access to sections of the European Nephrology Portal (ENP).
QUESTIONS
QUE
Q
UE
U
EST
STI
TI
TI
S
If you
ou
uh
ha
have
ave
av
ve any q
que
questions,
estion
stions
tions,,
ctt us a
at
do feel free to contact
[email protected]
m
ta.org
for full information
mation
m
on
Madrid2017
Main Ann
1016.indd
Sez1:41 7
Brochure
Era-Edta
NON
SOCI 0316.indd
4-11-2016
4-11-2016 6:38:39
5:51:13
www.era-edta2017.org
Madrid2017 Main Ann 1016.indd Sez1:42
4-11-2016 6:38:41